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Vaccines against exoerythrocytic stages of malaria remain ineffective in the face 
of limited knowledge on processing and presentation of parasite antigens in the liver. 
Here, we show that vaccine candidate circumsporozoite protein (CSP) is deposited and 
retained in human hepatocytes traversed by P. falciparum sporozoites for an extended 
time. Therefore, two reservoirs of hepatocytes contain malarial antigens: invaded and 
traversed cells. We demonstrate that CSP in traversed cells is long-lived, resides within 
several dynamic cellular compartments, and its turnover is regulated by distinct 
proteolytic systems, including the proteasome, lysosome and autophagy. We provide the 
first demonstration of endogenous processing of a malaria liver stage antigen by non-
infected, non-professional antigen-presenting cells (APCs) through multiple proteolytic 
systems. We propose that these processes are likely to generate a variety of antigenic 
products from CSP, as well as other sporozoite antigens shed into traversed cells, able to 
affect the effector phase of anti-malarial immunity. 
Development of Plasmodium parasites in the liver can be controlled by cytotoxic 
T lymphocytes (CTLs) recognizing malarial antigenic peptides presented by the major 
histocompatibility complex (MHC) I on the surface of hepatocytes. It is unknown if 
breaching of the plasma membrane during sporozoite traversal affects the ability of 
traversed hepatocytes to stimulate CTL responses, and if traversal affects the 
immunogenicity of nearby “non-traversed” hepatocytes in the infected liver. We show 
that traversed cells remain viable and competent to present endogenously processed 
antigen to CD8+ T cells.  Stimulated CTLs undergo the complete program of antigen-
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specific activation, including cytokine secretion, cytotoxic granule release, and 
proliferation. Soluble factors released by either traversed hepatocytes or by T cells 
activated on traversed hepatocytes do not impose traversal-specific in-trans effects on 
CTL activation. Finally, traversed hepatocytes endogenously presented a C-terminal 
epitope of CSP to specific CTLs, stimulating IFNγ production. Our data propose a novel 
view of traversed cells as a potential site of parasite-specific immune activation. 
Since protective immune responses achieved in experimental vaccination differ 
dramatically from the partial protection naturally acquired in malaria-endemic regions, 
we next investigated the repertoire of HLA-A*02-restricted CSP-specific CD8+ memory 
T cells in PBMCs from adults living in malaria-endemic Mali. While plasma of 28/45 of 
Malian adults included in the study had detectable CSP antibodies, PBMCs from only 
10/45 had functional ex vivo recall responses to CSP. Compared to malaria-naïve US 
volunteers, PBMC samples from Malian adults exhibited altered composition of the T 
cell compartment and increased expression of T cell exhaustion marker, PD-1. Our 
preliminary data demonstrate that T cell activation induced via TCR triggering could be 
facilitated by PD-1-specific, neutralizing monoclonal antibodies. However, it still needs 
to be discovered if malaria-specific memory T cell responses can be enhanced upon PD-1 
blockade in PBMCs from donors living in malaria endemic areas. 
Together, we propose a role for sporozoite traversal in CD8+ T cell responses 
against liver stage infection, and that novel vaccination strategies are needed to overcome 
immune dysregulation in T cell compartment found in populations from malaria-endemic 
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Chapter 1. INTRODUCTION 
1.1 Malaria is a public health challenge 
Malaria remains a major global public health burden, with one half of the world’s 
population living in areas with ongoing transmission. The parasitic infection caused an 
estimated 198 million cases and 584,000 deaths in 2013, 78% of which were children 
under the age of five in sub-Saharan Africa (World Health Organization 2014). These 
recent morbidity and mortality rates are the result of vast progress in the last decade due 
to improvements in interventions and access to them. However, significant challenges 
remain to reach the WHO vision of “A world free of malaria.” Future malaria programs 
are currently at a crossroads as in 2015, the WHO will establish a new strategy to reach 
2030. The development of an effective vaccine against malaria will be a high priority, 
cost-effective strategy in reaching these goals.  Efforts to generate a protective vaccine 
are hindered by many factors, including but not limited to antigenic variation, complex 
transmission patterns, and an inadequate understanding of immune mechanisms and 
correlates of protection, especially against pre-erythrocytic infection.  
1.2 Plasmodium species 
The causative agent of malaria is an apicomplexan parasite of the genus 
Plasmodium. Human malaria results from infection with one of five species through 
transmission by female Anopheles mosquitoes: P. falciparum, the cause of most severe 
disease, P. vivax, notable for the persistence of long-term, drug-resistant hypnozoite 
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reservoirs in the liver, P. malariae, P. ovale, and more recently recognized, the zoonotic 
P. knowlesi (Kantele & Jokiranta 2011). 
1.3 Plasmodium life cycle 
Plasmodium parasites have a complex life cycle alternating between sexual 
development in the mosquito and asexual development in the vertebrate host. When an 
infected female Anopheles mosquito harboring mature sporozoites in the salivary gland 
takes a blood meal to support egg production, sporozoites are deposited into the skin. 
These highly motile sporozoites (reviewed in (Montagna et al. 2012)) enter the 
bloodstream to reach their target organ, the liver, within minutes to hours (Yamauchi et al. 
2007). It is believed that sporozoites continue to migrate until ultimately invading a 
single hepatocyte, within which they will develop and replicate inside a parasitophorous 
vacuole (PV) over seven days in the case of P. falciparum (reviewed in (Mikolajczak & 
Kappe 2006)). Thousands of mature merozoites are released from the hepatocyte to 
invade erythrocytes, establishing the symptomatic blood stage infection and 
exponentially amplifying parasite load, as each infected erythrocyte yields 16-32 
daughter merozoites (reviewed in (Hafalla et al. 2011)). With each asexual cycle, the host 
develops characteristic periodic fevers, but symptoms may vary from asymptomatic to 
mild to severe as parasite load increases. In response to poorly understood stimuli, a 
portion of asexual parasites differentiate into male or female gametocytes, transmissible 
to the mosquito (reviewed in Drakeley et al. 2006). Upon taking a blood meal, female 
mosquitoes ingest gametocytes and foster the fertilization and development into 
ookinetes in the midgut. Ookinetes breach the midgut epithelium, transform into oocysts 
and then into sporozoites that travel to the salivary gland for transmission to the next host, 
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over two to three weeks. Utilizing a complex life cycle involving two hosts, three 
developmental sites (mammalian liver and blood, mosquito midgut), and several weeks’ 
time, it is an evolutionary marvel that malaria could present such a grave public health 
concern. 
1.4 Malaria pathogenesis 
Symptoms of P. falciparum infection are associated with erythrocytic infection 
and characteristically include cyclical fevers, commonly accompanied by chills, sweats, 
headache, and malaise, attacking with every 48-hour replication cycle. More severe 
malaria may be associated with anemia, coma, respiratory and neurological complications 
that can ultimately lead to death. These symptoms can represent the result of a complex 
balance between parasite replication and the immune response (reviewed in (Hisaeda et al. 
2005)). Pathogenesis partially results from the cytoadherence of parasitized erythrocytes 
to the vascular endothelium, mediated by expression of “knobs” of PfEMP1 on the 
erythrocyte membrane. This cytoadherence is associated with cerebral and placental 
malaria (reviewed in Maier et al. 2009). Most uncomplicated infections are resolved 
following treatment with artemisinin-based combination therapies (reviewed in (Visser et 
al. 2014). However, emergence of drug-resistant strains is an increasing concern, 
emphasizing the importance of developing a preventive vaccine. 
1.5 Sporozoite and liver stage biology 
While the erythrocytic forms of Plasmodium were discovered in 1880, the 
clinically silent, pre-erythrocytic stage was not located in the liver until almost 70 years 
later. Once in the liver, productive pre-erythrocytic development requires sporozoite 
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invasion of a single hepatocyte with formation of a PV, consisting of host- and parasite-
derived membranes, (reviewed in Lindner et al. 2011). Schizogony, replication, 
cytokinesis, and differentiation into thousands of merozoites follows as the PV grows to 
larger than the host hepatocyte (Sturm et al. 2009). Thousands of merozoites are then 
released from the hepatocyte to invade erythrocytes (reviewed in Mikolajczak & Kappe 
2006).  
Prior to exoerythrocytic form (EEF) development, however, the sporozoite must 
actively overcome physical barriers and innate immune responses in order to reach the 
target liver parenchyma (Hopp & Sinnis 2015, reviewed in Sinnis & Zavala 2012). 
Studies of early interactions between the sporozoite and mammalian host have been 
relatively limited until recently with the advancement of intravital imaging techniques 
(Tavares, Formaglio, Medvinsky, et al. 2013), but have begun to elucidate the events 
crucial for infection and priming of the adaptive immune response that occur even prior 
to sporozoites reaching the liver.  
1.6 Sporozoite motility 
1.6.1 Motility in apicomplexa 
Plasmodium belongs to the phylum apicomplexa, alongside other human and 
livestock pathogens Cryptosporidium, Toxoplasma gondii, Eimeria and piroplasms 
(reviewed in Montagna et al. 2012). All are unicellular, obligate intracellular parasites 
with motile invasive forms that must penetrate target organs for replicative infection. 
They share similar structural features that enable such motility: a polarized, elongated 
morphology and secretory apical organelles micronemes and rhoptries containing 
homologous proteins, and lack of cilia or flagella (Carruthers & Tomley 2008; Montagna 
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et al. 2012). This biology is essential for host cell recognition and attachment, 
establishment of the parasitophorous vacuole, and for remodeling of the host cell post-
invasion. 
1.6.2 Sporozoite journey to the liver requires active motility 
Because sporozoites were found in human blood immediately during and after 
blood feeding, it was initially thought that sporozoites were injected directly into the 
bloodstream (Fairley 1947). Later, Vanderberg suggested that sporozoites must be 
actively motile during parts of their journey to complete their “adventurous existence,” 
between the mosquito and mammalian host (Vanderberg 1974). He realized that while 
some sporozoites were deposited directly to the bloodstream, and those could be 
passively carried to the liver with blood flow, most sporozoites were probably injected 
into the skin, from which they must actively escape. Several studies in rodents have since 
demonstrated that most sporozoites are indeed injected into the dermis, and must actively 
migrate to the bloodstream (Sidjanski & Vanderberg 1997; Matsuoka et al. 2002; Amino 
et al. 2008). While about one hundred sporozoites are injected during a mosquito 
bloodmeal (Medica & Sinnis 2005), far fewer actually reach the target organ, the liver. 
About 20% of sporozoites remain in the proximal draining lymph node (Amino et al. 
2006; Yamauchi et al. 2007), and up to 5% stay the skin, where some may partially 
develop into EEFs (Gueirard et al. 2010; Voza et al. 2012).  
On a cellular level, Plasmodium sporozoites use two types of motility to travel 
from the dermal injection site to their ultimate site of replicative infection, hepatocytes: 
gliding and traversal (reviewed in (Sinnis & Zavala 2012)). Both methods depend on 
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secretion of micronemal components and have been observed experimentally in vitro and 
in vivo.  
Gliding, substrate-dependent motility without cilia or flagella, or major changes in 
cell morphology, is controlled by a subpellicular actinomyosin motor linked to the 
sporozoite surface by thrombospondin-related anonymous protein (TRAP) (reviewed in 
King 1988; Kappe et al. 2004). Gliding is observed experimentally as circular movement 
on glass, thought to reflect a similar pattern of gliding over a cell surface. Therefore, 
gliding is frequently used as an in vitro measure of sporozoite viability and motility 
(Lupton et al. 2015). TRAP is required for both gliding motility and productive infection. 
It is shed from the sporozoite surface, and is thus under investigation as a vaccine 
candidate (Sultan et al. 1997; Ejigiri et al. 2012). 
Traversal is the transmigration of sporozoites in and out of cells, and has been 
observed in many cell types (Vanderberg et al. 1990; Mota et al. 2001; Coppi et al. 2007; 
Amino et al. 2008) as well as in Toxoplasma and Eimeria sporozoites (Speer et al. 1997; 
Danforth et al. 1992). In vivo, Plasmodium sporozoite traversal is critical for dermal exit 
(reviewed in Sinnis & Zavala 2012). While traversal occurs extensively in vitro through 
monolayers of a single cell type, its function is unclear. Both gliding and traversal can be 
inhibited in vitro by anti-sporozoite antibodies in a dose dependent manner (Behet et al. 
2014).  
In addition to gliding and traversal, A third distinct motile behavior is used for 
cell invasion, which results in formation of the PV, the ultimate destination of the 
sporozoite. 
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1.6.3 Plasmodium traversal 
The first observations of active cell traversal by Plasmodium sporozoites in vitro 
were performed with P. berghei in peritoneal macrophages (Vanderberg et al. 1990). 
Phase contrast videomicroscopy revealed several types of interactions between 
sporozoites and rodent macrophages, which were described as: no interaction, interaction 
without entry, killing by the macrophage extracellularly, phagocytosis, phagocytosis 
followed by escape, active penetration, and death of the macrophage following entry and 
exit. Interestingly, these characterizations included both active and passive interactions 
whereas previously, it had been thought that sporozoites were passively phagocytosed by 
Kupffer cells This and other studies suggesting that sporozoites enter the liver 
parenchyma via Kupffer cells (Barnwell 2001; Frevert et al. 2006) raise questions of how 
sporozoites survive within these macrophages, cells specialized to phagocytose and 
destroy pathogens. It also presents the possibility for antigen presentation of sporozoite-
secreted proteins by macrophages.  
Cell traversal was subsequently observed in hepatocytes prior to invasion, which 
has been proposed to serve multiple roles: “activating” sporozoites for invasion, 
enhancing susceptibility of hepatocytes to subsequent invasion by releasing hepatocyte 
growth factor (HGF), immune evasion, by de-activating innate immune responses of 
Kupffer cells, and depositing antigen in non-target cells as a decoy (Mota et al. 2001; 
Mota et al. 2002; Mota & Rodriguez 2004; Zheng et al. 2014). Understanding of cell 
traversal by sporozoites was enhanced by the identification and disruption of sporozoite 
microneme protein essential for traversal  (SPECT, SPECT-2) (Ishino et al. 2004). 
Sporozoites deficient in SPECT and SPECT-2 proteins are competent to invade 
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hepatocytes at the same rate as wild-type sporozoites in vitro, questioning the 
hypothesized requirement for traversal prior to invasion (Mota et al. 2002).  
Recent live imaging studies in mice showed the first in vivo evidence of 
sporozoite traversal through hepatocytes (Tavares, Formaglio, Thiberge, et al. 2013). To 
reach productively invade, sporozoites breached the sinusoids through different 
mechanisms involving traversal: 53% traversed through endothelial cells lining the 
sinusoids, 24% through Kupffer cells, and the remaining minority crossed intercellular 
gaps independently of traversal. These in vivo studies also challenged the sporozoite 
“activation” hypothesis (Mota et al. 2002).  
There has been extensive speculation about the role of traversal in the life cycle of 
the parasite. With new innovations in live imaging of small animals using spinning disk 
confocal microscopy, this body of knowledge will continue to grow quickly. While much 
research has focused on the utility of traversal for the sporozoites, we believe our studies 
are among the first to address the effect of traversal through hepatocytes on the host.  
1.7 Circumsporozoite protein (CSP) 
Closely linked to traversal activity is circumsporozoite protein (CSP). Long since 
referred to as CSP, the major sporozoite surface protein and immunodominant antibody 
target in mice was first identified in P. berghei as Pb44 (Yoshida et al. 1980; Aikawa et 
al. 1981).   Anti-Pb44 monoclonal antibody 3D11 was observed to bind a protein coating 
the surface of mature, salivary gland sporozoites, as well as EEFs from P. berghei 
infected rats until 24 hours post-infection, but not later. These antibodies were shown to 
have a function in inhibiting the infectivity of sporozoites injected onto Balb/c mice. 
Therefore, CSP was quickly under investigation as a subunit vaccine, as whole sporozoite 
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vaccines were effective, but impractical (Yoshida et al. 1981). More than forty years later, 
CSP remains the single most advanced vaccine candidate. 
1.7.1 CSP has several essential roles 
Comprising up to twenty percent of total protein in mature sporozoites (Yoshida 
et al. 1981; Cochrane et al. 1982), CSP has several key functions for the sporozoite both 
in the mosquito and mammalian host (Ménard et al. 1997; Pancake et al. 1992; Stewart et 
al. 1987), making it essential for infectivity. It is first expressed at high levels in the 
mosquito midgut oocyst and is required for sporogony and sporozoite invasion into 
mosquito salivary glands (Nagasawa et al. 1987; Posthuma et al. 1988; Myung et al. 
2004). Once injected into the skin, it is important for gliding motility (Stewart & 
Vanderberg 1988) and adhesion to the target hepatocyte through recognition of heparan 
sulfate proteoglycans (HSPGs)(Pancake et al. 1992; Cerami et al. 1992; Pinzon-Ortiz et 
al. 2001).It is further utilized in sporozoite invasion of hepatocytes (Stewart et al. 1986).  
P. falciparum CSP continues to be expressed for the first five days of EEF development 
(Sacci et al. 2006; Mikolajczak et al. 2011). Its expression on the sporozoite surface as 
well as inside infected hepatocytes make CSP a potential target of specific antibody 
responses during invasion, as well as MHC-class-I restricted recognition by cytotoxic T 
lymphocytes (CTLs) inside hepatocytes.  
1.7.2 CSP functional domains 
The general structure of CSP, consisting of a tandem repeat region flanked by N- 
and C-terminal domains, is well conserved among different Plasmodium species, 
suggesting essential roles for each domain. Elucidation of the conformation of CSP has 
 10 
been challenging to crystallographers because of its unusual, repetitive structure (Doud et 
al. 2012). 
The N-terminus contains a signal sequence and Region I (RI), consisting of 5 
conserved amino acid residues, KLKQP, in all species studied except P. gallinaceum 
(NLNQP). The N-terminus has roles in cell adhesion, binding to mosquito salivary glands 
(Sidjanski et al. 1997; Myung et al. 2004) and to HSPGs in the liver (Rathore et al. 2002; 
Rathore et al. 2005). Cleavage occurs at RI by a parasite protease upon sporozoites 
contact with host hepatocytes (Coppi et al. 2005; Coppi et al. 2011). Functionally, this 
cleavage event switches sporozoite behavior from “adhesive,” to “invasive,” and is 
important for hepatocyte invasion (Coppi et al. 2011). Antibodies recognizing the RI site 
have been shown to inhibit cleavage of CSP and impair invasion in vitro infection and 
well as infection in vivo (Espinosa et al. 2015).Therefore, induction of N-terminal RI-
specific antibodies may be a desirable target of vaccination.  
Comprising 42% of the 3D7 reference strain of P. falciparum, the central tandem 
repeat region is a B-cell immunodominant stretch of 38-43 species-specific tetrameric 
repeats (Gandhi et al. 2014). The sequence bears no homology to other known proteins, 
though other Plasmodium proteins do contain tandem repeat sequences that are also 
immunogenic (Anders et al. 1986). While the exact function of the repeat region is 
unknown, it is essential in sporozoite development, as repeat deletion mutants in P. 
berghei fail to mature from oocysts to sporozoites (Ferguson et al. 2014). It is speculated 
to have a role in high avidity, multivalent interactions with glycosaminoglycans (GAGs) 
(Rathore et al. 2001).  
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Finally, the C-terminus of CSP contains a type I thrombospondin (TSR) domain 
that binds to HSPGs and HepG2 cells in conjunction with the N-terminus (Ying et al. 
1997).  While TSRs are common in other organisms and is found in TRAP, the CSP TSR 
is divergent (Tossavainen et al. 2006). The utmost 3’ end of CSP contains a predicted 
canonical glycosylphosphatidylinositol (GPI) anchor. 
1.7.3 CSP as target of adaptive immunity 
CSP is highly immunogenic, inducing antibody responses in natural infection and in 
sporozoite-based vaccination, making it a primary vaccine target (Nardin et al. 1999; 
Birkett et al. 2002). The central repeat region contains an immunodominant B cell 
epitope (Zavala et al. 1983; Zavala et al. 1985a), to which anti-repeat antibodies inhibit 
hepatocyte invasion, justifying its inclusion in antibody-inducing vaccines (Nussenzweig 
& Nussenzweig 1989; Persson et al. 2002). The C-terminus contains important, 
polymorphic T-cell epitopes Th2R (aa 326-343) and Th3R (aa 361-380) (Good et al. 
1988; De Groot et al. 1989; Zevering et al. 1994). MHC class I-restricted CSP-derived T 
cell epitopes and their significance to natural infection and vaccination will be discussed 
further below. 
1.7.4 Genetic diversity in CSP 
In the design of CSP-based vaccines, it is essential to consider the genetic 
variation often detected across Plasmodium strains. Overall evidence of the role of 
genetic polymorphisms in clinical outcomes of infection and protection following 
immunization vary across studies, however. In an in-depth prospective study of children 
in Mali, no associations were found between sequence variations in Th2R and Th3R and 
clinical malaria episodes, suggesting a lack of allele-specific protective immunity against 
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CSP in this region (Gandhi et al. 2014).  While sequence variation is found in these 
regions, CTLs specific to this region can be cross-reactive for other alleles (Lyke et al. 
2005). Follow-up studies to RTS,S trials in different settings have revealed different 
results, suggesting that strain-specific sequence variation in CSP was or was not 
implicated in vaccine failure (Waitumbi et al. 2009; Macete et al. 2007; Alloueche et al. 
2003).  
There are several possible explanations for the widespread diversity in CSP. 
Sequence variation may result from a combination of geographic separation of isolates 
(Tanabe et al. 2013) and selective pressure (Hughes 1991; Escalante et al. 2002). The 
variable number of repeats could be an immune evasion mechanism by the parasite by 
enhancing a non-protective response (Schofield 1990) or dictate the stability of CSP 
(Escalante et al. 2002). SNPs could result in generation of sequences giving rise to altered 
peptide ligands (Plebanski, Lee, et al. 1997; Gilbert et al. 1998), or reflect adaptation to 
bind salivary glands of different mosquito species (Kumkhaek et al. 2005). At present, 
the importance of genetic diversity in CSP in protective immunity is largely unclear.  
1.7.5 CSP is shed by motile sporozoites 
CSP is actively shed by gliding sporozoites in vitro (Stewart & Vanderberg 1988; 
Stewart & Vanderberg 1992) and is speculated to be retained in traversed cells. However, 
this has not been formally demonstrated. Prior to defining traversal as a cell migratory 
activity, CSP was observed microscopically in the cytosol of invaded cells (Hügel et al. 
1996). Hügel et. al. concluded that this CSP was a result of protein exported from inside 
the PV. However, with more recent understanding of traversal, another possibility is that 
CSP was shed during sporozoite traversal prior to, or after the hepatocyte had been 
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invaded by another (or the same) sporozoite. TRAP and erythrocyte-binding antigen 175 
(EBA-175) have also been found in trails of shed protein and lipids from motile 
sporozoites and are potentially deposited in traversed hepatocytes as well (Mota et al. 
2002). Thus, we speculated that non-infected traversed cells might serve as a reservoir of 
deposited malarial antigen in close proximity to the site of replicative infection in the 
liver. This would present two distinct possibilities for the immune response: serving a 
benefit to the host, by enhancing T cell activation, or a detriment, diverting specific T 
cells away from EEFs. 
1.7.6 CSP in immune evasion 
CSP is expressed at high levels, conserved among species and strains, and is a 
protective antigen in experimental animal vaccination. High levels of anti-CSP IgG have 
long been detected in naturally exposed individuals in hyperendemic regions (Nardin et al. 
1979; Offeddu et al. 2012). Yet, these antibodies do not afford protection in endemic 
settings (Hoffman et al. 1987), possibly because antibody titers are not induced or 
maintained at high enough levels to neutralize sporozoites. Together, these paradoxical 
features suggest a possible function of CSP in immune evasion (Schofield 1990), and 
could in part explain the poor immunity that results from natural infection.   
Besides the strong but ineffective immune responses against CSP, there are 
several lines of experimental evidence supporting a role for CSP in immune evasion. In 
infection of human hepatoma cell line HepG2 with P. berghei, CSP was implicated in 
controlling protein synthesis in non-invaded cells (Frevert et al. 1998). In this study, 
completed prior to the identification of cell traversal in 2001, CSP was shown to arrive in 
the cytoplasm of non-invaded cells by translocation through the plasma membrane by 
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“extracellular attached sporozoites.” It is now more commonly accepted that sporozoites 
shed CSP into the cytosol while traversing through a cell. These CSP-positive cells did 
not incorporate tritiated leucine from the culture medium immediately after co-cultivation 
with sporozoites, interpreted as CSP-directed shutdown of protein synthesis.  
CSP has been reported to specifically interfere with several functions of the host 
hepatocyte important in inflammation, by entering the cytoplasm following export from 
the PV in invaded hepatocytes and competing with NFκB for nuclear import (Singh et al. 
2007). However, we recently addressed several of these possible CSP-driven 
perturbations relevant to antigen presentation in the relevant cell type, human hepatocytes, 
using HC-04 cells. Our data show that HC-04 hepatocytes expressing either full-length or 
cleaved CSP maintain unaltered surface expression of MHC class I and transcript levels 
of other components of the MHC class I processing pathway (Ma et al. 2013).  Altogether, 
while there is evidence for a role of CSP in alteration of host cell function and immune 
evasion, some studies warrant re-interpretation following newer findings about cell 
traversal. 
1.8 Immunology of natural malaria infection 
Natural exposure to malaria results in the development of clinical immunity, 
incomplete protection that may prevent the development of malaria symptoms by limiting, 
but not completely preventing infection (Offeddu et al. 2012). In highly endemic regions, 
exposed individuals develop partial clinical immunity with age and continued exposure, 
resulting in decreased illness and mortality while experiencing repeated re-infection 
(Baird et al. 1998). The acquisition of immunity appears to depend on the overall 
accumulation of exposure: in regions of high transmission, young children bear the 
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biggest disease burden, which wanes with age, while in lowly endemic areas, individuals 
of all ages are affected (Miller et al. 1994). Adults in endemic regions are often 
asymptomatic yet parasitemic, providing ongoing parasite reservoirs for continued 
transmission to the community. As of yet, no correlates or signatures of protective 
immunity have been defined in natural exposure. While more robust immune responses 
are directed against blood than liver stage antigens, which have a higher level and longer 
duration of exposure, our studies focus on the less understood responses to liver stage 
antigens.  
1.8.1 Natural infection: Humoral responses  
Antibodies to liver stage antigens, particularly CSP, are frequently detected in 
children and adults in malaria-endemic regions (reviewed in Offeddu et al. 2012). Serum 
samples from exposed individuals bind to the sporozoite surface, reflecting the pattern of 
staining observed using monoclonal antibodies against CSP. The percentage of 
populations in endemic regions whose sera recognize sporozoites increases with age but 
independently of current blood stage infection. Most studies of antibody responses 
against CSP have focused on IgG specific to peptides representing the central repeat 
region, detection of which generally servers as a surrogate for the whole protein. 
However, at least one study, of a population in endemic Gabon, detected antibodies 
against CSP RI in a small proportion of donors whose serum lacked reactivity with the 
central repeat (Del Giudice et al. 1988). A protective function of antibodies against the N-
terminus were suggested by a report of association between antibodies to this region with 
protection from clinical malaria in children in Tanzania (Bongfen et al. 2009).  While a 
causal relationship has yet to be established, it would be reasonable to expect that 
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antibodies recognizing the N-terminus could have different functions than those to the 
repeat region because of the distinct functions of each domain of the protein. Thus, it may 
be important for studies of humoral immunity to CSP to consider responses to each CSP 
domain, namely N- and C-termini as well as the repeat region. As such, our studies have 
focused on finer specificities of antibodies to CSP. As of yet, however, antibodies to CSP 
appear to signify exposure to malaria rather than protection.  
Other sero-epidemiological studies have investigated naturally induced antibody 
responses to vaccine candidates including LSA-1, LSA-3 TRAP, EXP-1, and STARP 
individually, and some have utilized high throughput methods of screening hundreds of 
Plasmodium antigens (reviewed in Doolan 2011). A recent study of Malian children 
associated protection with the breadth of antigens recognized instead of responses to 
single antigens (Daou et al. 2015), similar to what has been observed in vaccination 
studies (Trieu et al. 2011).  
1.8.2 Natural infection: Cellular responses 
Because MHC class I-restricted CD8+ T cell responses are important in 
protection following vaccination (discussed below), the identification of protective class 
I-restricted T cell epitopes from liver stage antigens is a high priority for vaccine 
development. Ex vivo studies of naturally exposed individuals are technically difficult, as 
the frequency of specific T cells of interest are likely rare; a methodological study 
showed that at least three simultaneous approaches of re-activation of memory T cell 
responses ex vivo were required to sensitively identify Plasmodium-specific T cells in 
PBMCS from exposed individuals in The Gambia (Flanagan et al. 2001). Variety of HLA 
haplotypes and its high variability between different regions in endemic areas poses 
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another challenge, to predict which peptides epitopes are likely to be presented. 
Nonetheless, many studies have investigated HLA-restricted, liver stage specific T cell 
epitopes (Doolan et al. 1991; Sedegah et al. 1992; Aidoo et al. 1995; Blum-Tirouvanziam 
et al. 1995), to be discussed further in Chapter 4. 
1.8.3 Natural infection: Immune dysregulation 
Populations at risk of malaria often live in regions afflicted by poverty, 
malnutrition, and co-infection with chronic helminth infections or HIV. Therefore, 
natural immune responses to malaria occur in the context of other co-morbidities that can 
profoundly impair the immune response. Malaria itself manifests more as a chronic than 
acute infection in settings of repeated and recrudescent illness. There is a well-
documented overall impairment of B-cell memory responses in natural exposure (Weiss 
et al. 2010; Liu et al. 2012) and exhaustion of T-cell responses, mediated by immune 
inhibitory receptors such as PD-1 (Horne-Debets et al. 2013). Overcoming these 
challenges to mounting effective immune responses will be critical in designing effective 
vaccines for malaria in the developing world. 
1.9 Malaria liver stage vaccines 
Vaccines targeting the pre-erythrocytic stage of malaria infection are an optimal 
approach because abrogation of this pre-symptomatic infection blocks the onset of 
clinical symptoms of malaria as well as transmission. However, complete protection 
against liver stage infection is challenged by the fact that only one sporozoite that invades 
a hepatocyte can be sufficient to propagate infection. Therefore, a pre-erythrocytic 
vaccine must completely eliminate every single sporozoite or infected hepatocyte. 
 18 
Research in small animals, non-human primates, and humans support the feasibility of a 
protective vaccine. 
1.9.1 Attenuated sporozoite vaccines 
The vaccine “gold standard,” capable of generating sterile protection in humans is 
the irradiated sporozoite vaccine (IrrSpz) (Nardin et al. 1999). Protection following 
immunization of A/J mice with irradiated P. berghei sporozoites was first demonstrated 
in 1967 (Nussenzweig et al. 1967), followed shortly thereafter by successful 
immunization of Balb/c mice (P. berghei, P. yoelii) and rhesus macaques (P. knowlesi) 
(Gwadz et al. 1979). Radiation-attenuated P. berghei and P. falciparum sporozoites 
exhibit comparable motility, hepatocyte invasion rates, and early EEF development to 
wild-type sporozoites (Mac-Daniel et al. 2014; Silvie et al. 2002). The same vaccination 
approach has elicited protection in humans. The dosing requirements to show protection 
in humans is very high: protection may require at least 1,000 bites by infected, irradiated 
mosquitoes (P. falciparum, P. vivax), which clearly does not reflect the manner of natural 
infection by mosquito bite, and is not a practical vaccination strategy (Clyde, McCarthy, 
et al. 1973; Clyde, Most, et al. 1973; Clyde et al. 1975; Edelman et al. 1993). 
Genetic attenuation is also under investigation following initial studies in mice 
inducing long-term immunity, though some have experienced problems with 
breakthrough infections due to insufficient attenuation (Mueller et al. 2005; Tarun et al. 
2007; van Dijk et al. 2005). The first proof-of-principle infection of humans with p52-
/p36- genetically attenuated P. falciparum sporozoites effectively induced anti-CSP 
antibodies that inhibited sporozoite invasion, as well as IL-2, TNFα, and IFNγ secreting 
CD4+ and CD8+ T cells upon re-stimulation with sporozoites or individual liver stage 
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antigens (Spring et al. 2013; Finney et al. 2014). However, one of six volunteers infected 
with the attenuated parasite developed blood stage parasitemia. Thus, future genetically 
attenuated parasites must be further attenuated to avoid causing illness.  
A third approach to whole sporozoite vaccination is wild-type sporozoite infection 
under chemoprophylaxis (CPS), which requires 20-fold fewer mosquito bites for sterile 
protection than IrrSpz immunization (Nahrendorf et al. 2014). As chloroquine 
specifically kills erythrocytic stage parasites, this immunization strategy presumably 
exposes the vaccinee to the full breadth of liver stage antigens, as well as limiting the 
quantity of blood stage antigens. 
Irradiation- and genetically-attenuated parasites proceed through early stages of 
liver stage development, expressing multiple sporozoite and liver stage antigens (SLA), 
but arrest prior to merosome maturation. CPS is the only whole sporozoite method of 
vaccination that proceeds to early blood stages, reviewed in (Nganou-Makamdop & 
Sauerwein 2013; Epstein & Richie 2013). Importantly, protection is not induced by 
inoculation with heat-killed sporozoites (Alger & Harant 1976), indicating that 
sporozoites must be viable for successful vaccination. Altogether, attenuated whole 
sporozoite vaccines clearly demonstrate that SLA can confer protection, but this method 
of vaccination is impractical. Thus, these findings have led to further investigation of 
subunit vaccination with single or multiple SLA.   
1.9.2 Subunit vaccines 
The most advanced subunit vaccine to date is the CSP-based RTS,S, which 
contains the central repeat and C-terminus of CSP fused to HBSAg. As protection has 
been achieved in experimental models in CSP-tolerized mice (Kumar et al. 2006), other 
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pre-erythrocytic antigens under study include thrombospondin-related adhesion protein 
(TRAP), liver-stage antigen (LSA), exported protein 1 (Exp-1), and cell-traversal protein 
for ookinetes and sporozoites (CelTOS) (reviewed in (Duffy et al. 2012)). 
RTS,S/AS01 
The RTS,S/AS01 vaccine, (named for Repeat, T-cell epitopes, fused to Hepatitis 
B S antigen, expressed in yeast with non-fused S antigen) developed in part by 
GlaxoSmithKline, has been tested in Phase III trials in Africa. The vaccine-like particle 
(VLP) displays the repeat and C-terminal domains of CSP fused to hepatitis B surface 
antigen (HBSAg) (Cohen et al. 2010). Clinical trials in Africa resulted in 50% protection 
in non-exposed volunteers (Kester et al. 2009), but only 30-45% in children, with fewer 
infants protected (6-12 weeks old) than older children (5-17 months).  (Bejon et al. 2013; 
Olotu et al. 2013). A recent high throughput study of the breadth and magnitude of 
antibody responses to a large panel of liver- and blood-stage antigens following RTS,S 
vaccination showed decreased overall parasite-specific antibody responses in RTS,S 
vaccinated, versus control-vaccinated children in Mozambique (Campo et al. 2014). CSP 
was, expectedly, an exception. These findings suggest that the immune responses induced 
by RTS,S inhibit sporozoite invasion, thus blocking infection and exposure to other liver 
and blood stage antigens that would boost antibody responses. While the partial 
protection appeared to be associated with antibodies (Kester et al. 2009) and CSP-
specific CD4+ T cells (Good & Doolan 2010) but not CD8+ T cells, correlates of 
protection have not been firmly defined. 
Other pre-erythrocytic vaccines in clinical trials include PfCelTOS FMP012, 
CSVAC, and Ad35 vectored CS and RTS,S-AS-1 combined in heterologous prime-boost 
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schedule (Phase 1), and the ChAd63/MVA in Phase 2 (reviewed in (Arama & Troye-
Blomberg 2014)).  
1.10 Mechanisms of protective immunity following experimental 
liver-stage immunization 
Depending on the experimental model, many immune components are implicated 
in the response to liver stage infection, including antibodies, CD4+ and CD8+ T cells, 
gamma delta T cells, NK, and NKT cells, (Duffy et al. 2012; Stanisic et al. 2013). 
Immune mechanisms required for protection have been shown to include antibodies, 
CD4+ and CD8+ T cells, interferon gamma (IFNγ) and/or tumor-necrosis factor alpha 
(TNFα) in different experimental mouse and non-human primate models (Doolan & 
Hoffman 2000). These studies illustrate the complex nature of the interactions involved 
in each host-parasite combination. 
1.10.1 Vaccine-induced anti-sporozoite antibodies 
There are several lines of experimental evidence supporting protective roles of 
antibodies in animal models. In early studies of irradiated sporozoite-based vaccination, 
sera of immunized animals and humans exhibited “sporozoite neutralizing activity” 
(SNA) that could inhibit sporozoite infectivity (Nussenzweig et al. 1969). Moreover, 
antibodies targeting CSP were specifically implicated in this neutralization. Passive 
transfer of monoclonal antibodies have provided protection against infection with P. 
berghei (Potocnjak et al. 1980) and P. yoelii (Charoenvit et al. 1991) sporozoites in mice 
and P. falciparum, P. vivax, and P. knowlesi in chimpanzees and monkeys (Nardin et al. 
1982; Cochrane et al. 1982). Recently, high titers of anti-P.falciparum CSP antibodies 
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induced by vectored-immune prophylaxis have partially protected mice from infection 
with P. berghei chimeric parasites expressing P. falciparum CSP (Deal et al. 2014).  
Possible functions of sporozoite-specific antibodies in protection against infection 
could include sporozoite killing through opsonization, inhibition of hepatocyte invasion, 
recognition and elimination of infected hepatocytes through antibody-dependent cellular 
cytotoxicity (ADCC), or recognition of mature merozoites and inhibition of erythrocyte 
invasion (reviewed in Casares & Brumeanu 2010). Antibodies against sporozoite surface 
proteins, including CSP, have been shown to inhibit sporozoite motility in the skin of 
mice and prevent invasion (Vanderberg & Frevert 2004; Vanderberg et al. 2007; Kebaier 
et al. 2009). The same has yet to be demonstrated in humans. However, in vitro studies 
have shown that human monoclonal antibodies against CSP generated from protected, 
vaccinated individuals inhibited sporozoite gliding on glass and invasion through HC-04 
cells, in a dose-dependent manner (Clement et al. 2012). In vivo, passive transfer of these 
human anti-CSP antibodies protected humanized uPA-SCID mice from P. falciparum 
infection one day post administration (Foquet et al. 2013). The injection of 400 µg anti-
CSP IgG led to plasma concentrations of about 500 - 1200 EU/mL in mice just prior to 
challenge, and was sufficient to protect mice from mosquito bite challenge.  
Overall, evidence from mice and non-human primates showed that high levels of 
antibodies against CSP could mediate protection, and were thought to be sufficient 
following IrrSpz immunization in humans as well. But, even though RTS,S is associated 
with induction of anti-CSP antibodies, it provides only partial, short-term protection. 
Therefore, the sufficiency of CSP-specific antibodies in humans, whether induced 
following natural infection for immunization, remains unclear (Grüner et al. 2007; Behet 
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et al. 2014). As some RTS/S induced antibodies have sporozoite inhibitory activity in 
vitro and in humanized mice, it is possible that CSP antibodies following vaccination in 
humans are not generated at high enough levels, or titers decline too rapidly.  
Several studies of immunized individuals associate protection with increased 
antibody responses to multiple sporozoite- and liver-stage antigens, instead of a single 
antigen (John et al. 2005; Trieu et al. 2011).  
1.10.2 Vaccine-induced αβ T cells 
Independently of antibodies, T cells have been implicated in protection following 
attenuated-sporozoite immunization. In early studies, the majority of P. berghei 
sporozoite-immunized B-cell deficient mice, 64%, were protected from sporozoite 
challenge, demonstrating a role for an antibody-independent mechanism of protection 
(Chen et al. 1977). In the same study, all T-cell deficient mice were susceptible to 
challenge post-vaccination with x-irradiated sporozoites. Selective depletion of CD8+ or 
CD4+ T cells has demonstrated important roles for each T cell subset, reviewed in (Duffy 
et al. 2012): CD8+ T cells are crucial in protection from P. berghei in rats (Schofield et al. 
1987) and P. yoelii yoelii 17X NL in BALB/c mice (Weiss et al. 1988), while depletion 
of CD4+ subsets did not impair protection. A dependence on CD8+ T cells for protection 
has been demonstrated in several mouse studies (reviewed in (Hafalla et al. 2011)), albeit 
with different efficacy, suggesting that MHC class I haplotypes may play an important 
role in parasite-specific immune surveillance. 
CD8+ T cells recognizing CSP in the context of MHC class I can afford against 
sporozoite challenge in mice. Mouse models have established requirements for very high 
amounts of circulating CSP-specific CD8+ T cells (exceeding 1% of total CD8+ cells) 
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(Schmidt et al. 2008), and the long-term presentation of CSP (Cockburn et al. 2010) to 
maintain these responses. High throughput studies using novel methods for identifying T 
cell specificities induced following natural exposure and vaccination in humans are under 
way (Grubaugh et al. 2013).  
CD4+ T cells generally offer a supportive and secondary role in immunity to liver 
stage after CD8+ T cells, affording protection in the absence of CD8+ cells (Oliveira et al. 
2008), and facilitating and maintaining CD8+ responses (Carvalho et al. 2002; Overstreet 
et al. 2011). Depletion of CD4+ T cells following immunization with P. yoelii 
sporozoites reduced protection, measured as liver parasite burden, though not to the 
degree of CD8+ depletion (Rodrigues et al. 1993). However, passive transfer of a CD4+ 
clone specific for a single non-CSP P. berghei sporozoite and blood stage antigen was 
sufficient to provide protection in mice (Tsuji et al. 1990).  
In humans, IFNγ+ CD4+ and CD8+ T cells have been detected upon restimulation 
following sporozoite or CSP-based immunization (Moreno et al. 1991; Calvo-Calle et al. 
2005; Seder et al. 2013; Spring et al. 2013; Roestenberg et al. 2009). But, their 
requirements for protection have not been demonstrated.  
1.10.3 Vaccine-induced protective T cell effector functions 
Multiple T cell effector mechanisms are implicated in liver stage protection, 
including direct cytotoxicity of infected hepatocytes, bystander killing through cytokine 
secretion, and helper T cell functions (reviewed in (Stanisic et al. 2013). The complexity 
apparent from these lines of evidence, mostly from rodent studies, indicates there are 
likely multiple, redundant mechanisms of protection (Doolan & Hoffman 2000).  
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Direct elimination of infected hepatocytes could occur through perforin-granzyme 
release or Fas/FasL interactions. The occurrence of such direct recognition and killing is 
supported by in vitro presentation of CSP from primary P. berghei infected hepatocytes 
to specific CD8+ T cells in a proteasome-dependent manner (Bongfen et al. 2007). 
Inhibition of P. yoelii development in bone marrow chimeric mice show a requirement 
for peptide recognition by cognate T cells on liver parenchyma supports this killing 
mechanism in vivo (Chakravarty et al. 2007). Furthermore, TAP-1 is required for 
activation of transferred CD8+ T cells specific for the H-2Kb-restricted SIINFEKL 
epitope within CSP of P. berghei CS5M (Cockburn et al. 2011). Recent live imaging 
studies in mice co-infected with MHC-matched and mismatched P. berghei strains have 
demonstrated elimination of only hepatocytes infected with parasites contained cognate 
epitopes, demonstrating exclusively direct, and not bystander-mediated, killing of 
infected hepatocytes (Cockburn et al. 2014). 
Multiple studies demonstrate important roles for pro-inflammatory cytokines in 
protection. Perforin-deficient and Fas-mutant C57BL/6 mice were both protected from P. 
berghei challenge following vaccination (Renggli et al. 1997). IFNγ depletion abrogated 
protection in P. berghei immunized rats (Schofield et al. 1987). We have recently found 
that P. berghei infection of HC-04 cells in vitro can be limited by the soluble factors 
released from bystander-activated CTLs, which can be mostly recreated with a 
combination of TNFα and IFNγ (S. Baer et.al., unpublished). These findings support 
other in vitro studies illustrating a dose- and time-dependent control of P. yoelii EEFs by 
TNFα (Depinay et al. 2011). These studies raise the question of a role for traversed cells 
in bystander-mediated control of EEFs. We speculated, that if sporozoite antigens shed 
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during traversal can be presented, recruit and activate specific CTLs to the liver proximal 
to infected cells, they could play a part in immunity against liver stage infection. 
Altogether, sterile protection seen in rodent models is mediated by anti-sporozoite 
antibodies and T cells targeting liver stage antigens, with a common requirement for 
CD8+ T cells, but the precise correlates of protection relevant to human infection have 
yet to be determined. Technical challenges limit the ability to definitively determine 
which liver stage antigens may be presented by invaded and/or traversed hepatocytes to 
elicit direct T cell activation. 
1.11 Experimental models of malaria Infection: advantages and 
limitations 
Rodent models utilizing multiple mouse and rat strains are exploited for studies of 
malaria-associated immunity and pathology, despite differences in natural history of 
disease from that in humans. These experimental models use parasites isolated from their 
natural host, Thamnomys rutilans, which have been adapted for use in laboratory mice or 
rats, further complicating assessment of pathogenesis and induction of natural host-
specific immunity. These host-parasite interactions are incredibly complex, illustrated as 
differential susceptibilities of rodents from different laboratory strains to challenge with 
different Plasmodium species. For example, BALB/c mice are more susceptible to 
infection with P. yoelii, requiring a lower sporozoites dose to become infected, while 
C57BL/6 are more susceptible to P. berghei (reviewed in Nganou-Makamdop & 
Sauerwein 2013)) Nonetheless, rodents remain the most convenient  animal model of 
infection and immunity, as compared to non-human primates and humans. Some of the 
most insightful findings from rodents have defined the dynamics of early events of 
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infection, from sporozoite inoculation to its destination in the skin, lymph node, or liver 
(reviewed in (Wykes & Good 2009) 
Different genetic backgrounds of inbred mice and Plasmodium species are 
selected as tools to study specific phenomena thought to relate to human malaria 
infection (reviewed in (Zuzarte-Luis et al. 2014). Briefly, three common species utilized 
in the laboratory include P. berghei, P. yoelii yoelii, and P. chabaudi. P. berghei is used 
to recapitulate a model of cerebral malaria upon infection in C57BL/6 mice. It is useful 
for the availability of tools for genetic manipulation and high in vitro infection rates of 
human hepatocyte lines (Hollingdale et al. 1983) and primary hepatocytes (Long et al. 
1989). P. yoelii yoelii is thought to invade and develop most similarly to P. falciparum in 
vitro, sharing the requirement for CD81, unlike P. berghei, which does not require CD81 
for hepatocyte invasion (Silvie et al. 2003). Finally, P. chabaudi is often utilized to study 
illness that is most similar to that caused by P. falciparum, including pathogenesis due to 
erythrocyte sequestration and antigenic variation. Most recently, the use of several 
chimeric mice with humanized livers allow monitoring of the development of P. 
falciparum liver stage infection, but in the absence of adaptive immunity (Legrand et al. 
2009).  
Mice are frequently used in early stages of vaccine testing. However, protective 
antimalarial immunity in mice has been readily achieved in many vaccine models using a 
variety of antigens. These studies have rarely translated into success using the same 
vaccine design in humans, questioning the utility of antigen discovery and validation of 
vaccine efficacy in mice. Instead, rodent models may have more utility in defining 
protective immunological correlates, such as the abundant evidence for protection from 
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CSP-specific CTLs, to inform vaccine design and studying cellular host-pathogen 
interactions. 
Since there is clearly no true small animal model of P. falciparum malaria illness 
(Miller et al. 1994), we often turn to in vitro studies, which present their own limitations. 
In vitro studies are hindered by low invasion rate, inefficient EEF development, 
biological variability in sporozoites production, and often subjective measures of 
infection. Nonetheless, in vitro infection of human cells with P. falciparum has been the 
optimal experimental system for our studies of sporozoites traversal, antigen presentation, 
and T cell activation.  
1.12 Thesis overview 
The enormous body of research on malaria in humans done so far is still 
insufficient to undertake a rationale approach to developing effective vaccines against 
pre-erythrocytic infection. While liver-stage-specific CD8+ T cells are accepted to be 
important in protection, it remains uncertain how to induce a strong, long-term effector 
memory T cell pool that can efficiently home to and reside in the liver. We used two 
infection models to develop a better understanding of CTL responses to liver-stage 
infection: in vitro infection, closely investigating sporozoite traversal, and memory 
responses mounted by peripheral blood from healthy adults living in malaria-endemic 
Mali.  
 
The main goals of the study were to:  
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a. Determine if liver stage antigen implicated in anti-malarial immunity, 
circumsporozoite protein, can be processed and presented by hepatocytes 
traversed by P. falciparum 
b. Determine if traversed hepatocytes can activate CD8+ T cells in an 
antigen-specific, MHC-class I-restricted manner 
c. Examine humoral and cellular responses against CSP in peripheral blood 
of naturally exposed adults    
1.12.1 Experimental system 
We sought to use an in vitro model of sporozoite infection and traversal relevant 
to human infection with P. falciparum. We employed two primary tools: human 
hepatocyte line HC-04 and the 3D7-HTGFP strain of P. falciparum, as described in 
Materials and Methods. HC-04 is the only immortalized cell line shown to support the 
development of both P. falciparum and P. vivax EEFs. P. falciparum EEF development is 
difficult to achieve in vitro and optimization of such methods were the primary goal of 
many studies (March et al. 2013; Ng et al. 2014; Tao et al. 2014; Zou et al. 2013; 
Prudêncio et al. 2011). We routinely observe infection rates, as measured by GFP 
percentage, of around 0.1% at maximum. However, sporozoites readily traverse through 
hepatocytes in vitro, as we will show in Chapter 2, making traversed cells available for 






Chapter 2. HUMAN HEPATOCYTES TRAVERSED BY P. 
FALCIPARUM SPOROZOITES IN VITRO RETAIN 
CIRCUMSPOROZOITE PROTEIN WITH DYNAMIC 
SUBCELLULAR LOCALIZATION 
 
This chapter contains material adapted from the manuscript: 
 
Trop S, Dumoulin P, Ma J, Zhang H and J Levitskaya. Traversed hepatocytes retain, 
process and present Plasmodium falciparum circumsporozoite protein for CD8+ T 
cell recognition. 
2.1 Introduction 
The liver stage of Plasmodium infection is an optimal target of protective 
vaccines because abrogation of this asymptomatic phase will prevent progression to 
clinical malaria. Yet, to date, an effective and practical vaccine has not been developed. 
Since immune responses must be initiated early enough to prevent development of 
hepatic merozoites, we investigated the immunological implications of the initial 
interactions between sporozoites and hepatocytes:  cell traversal. During sporozoite 
traversal, or migration in and out of cells, the sporozoite breaches the host plasma 
membrane, and secretes antigenic proteins, including circumsporozoite protein (CSP). 
Sporozoites are covered with CSP, the abundant, immunodominant sporozoite 
antigen that is transcribed in P. falciparum EEFs for five days (Sacci et al. 2006). Since 
CSP is actively shed apically by sporozoites during gliding motility (Stewart, Michael J., 
Vanderberg 1988; Stewart & Vanderberg 1991), we hypothesized that it could also be 
released into hepatocytes during cell traversal. It is conceivable that CSP-specific CD8+ 
T cell responses may target any cell containing this antigen and expressing MHC class I, 
including invaded as well as traversed hepatocytes. However, studies on the presence and 
turnover of CSP in traversed cells not containing a developing parasite have never been 
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conducted (Hügel et al. 1996). Accordingly, no knowledge on the immunological 
characteristics of traversed hepatocytes as potential targets for CD8+ T cell responses is 
currently available. 
In this study, we systematically characterized the retention and processing of P. 
falciparum CSP by traversed human hepatocytes. We demonstrated that CSP deposited in 
traversed cells is long-lived, resides within multiple cellular compartments and serves as 
a substrate for degradation by several proteolytic machineries which are expected to be 
presented by both canonical and non-canonical processing pathways resulting in MHC 
class I presentation.  
2.2 Materials and Methods 
Cell lines 
Human hepatocyte line HC-04 (Sattabongkot et al. 2006) was obtained from 
ATCC (Manassas, VA) and maintained in “complete medium”: IMDM containing 100 
U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine (Gibco, Grand Island, NY) 
and 2.5% fetal bovine serum (FBS) (Corning Cellgro, Manassas, VA). Cryopreserved 
primary human hepatocytes were obtained from Triangle Research Labs (Research 
Triangle Park, NC) and maintained in complete medium containing 10% FBS.  
Isolation of P. falciparum sporozoites 
P. falciparum 3D7-HTGFP parasite strain (Talman et al. 2010) was kindly 
provided by R. E. Sinden (Imperial College, London, UK). Female Anopheles stephensi 
mosquitoes were fed with blood containing P. falciparum gametocytes generated in the 
Insect and Parasite Core Facility (Johns Hopkins Malaria Research Institute, Baltimore, 
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MD). Mosquitoes were maintained on 10% sucrose containing penicillin, streptomycin 
and gentamicin for 17 days prior to sporozoite isolation from the thoraces of 800-1000 
mosquitoes per experiment as previously described (Ma et al. 2013). 
P. falciparum infection and isolation of traversed hepatocytes 
HC-04 cells were seeded in 12-well plates at a density of 6.5 x 104 cells per well 
72 h prior to infection. P. falciparum sporozoites were added at 1:1 sporozoite-to-
hepatocyte ratio in complete medium containing 0.2 µg/ml of fluoro-emerald, fluoro-ruby 
or Alexa Fluor 647 conjugated 10,000 MW dextran (Molecular Probes, Grand Island, 
NY). Alexa Fluor 647 conjugated dextran was used for cell sorting prior to 
immunofluorescence experiments. In control experiments cytochalasin D (Sigma-Aldrich, 
St. Louis, MO) treated or untreated sporozoites were incubated on ice for 30 min prior to 
infection. Plates were centrifuged at 380 x g for 5 min without brake. Three hours post-
infection, cells were washed three times with PBS containing 10% FBS. Separation of 
traversed from nontraversed, propidium iodide (PI) negative, hepatocytes was done 3-4 h 
pi using a MoFlo Cell Sorter (Beckman Coulter, Indianapolis, IN). To assess parasite 
development, percentages of GFP+PI- HC-04 cells were determined by flow cytometry 
72 h pi. 
Immunoblotting 
Traversed HC-04 cells were isolated by flow-cytometry based sorting 2 h pi,  re-
seeded and propagated with or without relevant treatment as described above, collected 
with 0.05% Trypsin-EDTA, washed with PBS, lysed with RIPA buffer (Cell Signaling 
Technology, Danvers, MA) on ice and 2x Laemmli Buffer (Bio-Rad, Hercules, CA) was 
added. Sonicated and boiled (95°C, 5 min) cell lysates were resolved on 10% Criterion 
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Tris-Glycine SDS-PAGE gels (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). 
Membranes were blocked in 5% non-fat milk in 0.1% Tween-20/PBS (PBST) and 
incubated with primary antibodies overnight in 5% milk/PBST at 4°C followed by 
washing and incubation with secondary antibody for 1 h at room temperature. The 
following antibodies were used: anti-PfCSP clone 2A10 (Zavala et al. 1985b) (kind gift 
of Dr. F. Zavala, JHMRI), anti-β-actin (Sigma, St. Louis, MO), anti-polyubiquitin (Enzo, 
Farmingdale, NY), anti-LC3B (Cell Signaling Technology, Danvers, MA) and anti-
mouse or anti-rabbit IgG-HRP (GE Healthcare, Piscataway, NJ). Membranes were 
developed with ECL Prime reagents and exposed to film (GE Healthcare). 
Immunofluorescence microscopy 
Sorted hepatocytes were propagated on collagen-coated coverslips for 24, 48 or 
72 h (NeuVitro, El Monte, CA). Coverslips were washed three times in PBS, fixed for 20 
minutes in 4% paraformaldehyde, permeabilized/blocked with 0.1% Triton X-100, 10% 
goat serum and 1% BSA in PBS and incubated with the following primary antibodies for 
1 h at room temperature: anti-CSP clone 2A10 (1 µg/ml) and parasite anti-Hsp70 clone 
4C9 (2 µg/ml) kindly provided by F. Zavala (JHMRI, JHU); anti-LAMP1 (Sigma), anti-
EEA1, -LC3B, -p62, -Rab7 (Cell Signaling Technology), anti-ubiquitin-protein 
conjugates (Enzo). Mouse IgG2a or normal rabbit serum (Sigma, St. Louis, MO) were 
used as relevant isotype control antibodies. After washing with 1% BSA in PBS, 
coverslips were incubated with secondary goat anti-mouse IgG-Alexa Fluor 594, isotype 
specific anti-IgG2a Alexa Fluor 488 or anti-IgG1 Alexa Fluor 488, or goat anti-rabbit 
IgG-Alexa Fluor 488 antibodies (Molecular Probes, Grand Island, NY) and mounted with 
ProLong Gold containing DAPI (Molecular Probes). Widefield fluorescence microscopy 
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was performed on a Nikon 90i upright microscope and images were acquired with a 
Hamamatsu ORCA 1394 camera and Volocity software (Perkin Elmer, Akron, OH). 
Patterns of CSP were classified visually as either punctate, contained within a single large 
aggregate, nuclear, or cytosolic. Overlap coefficients of CSP and markers of cellular 
compartments were calculated in Volocity as the percentages of the surface area of CSP 
that co-localized with the indicated cellular marker using automated thresholding to 
identify objects.  Overlaid micrographs of co-localized points, as determined by same 
thresholds, were generated using the RG2B plugin in ImageJ (Rasband 2012).  
Antibody staining and flow cytometry 
For intracellular detection of P. falciparum CSP and Hsp70, monoclonal 
antibodies 2A10 and 4C9 were directly conjugated to fluorophores using Zenon labeling 
kit for IgG2a and IgG1 following manufacturer’s instructions (Molecular Probes, Grand 
Island, NY). Cells were fixed and permeabilized prior to intracellular staining as 
described above. Data were analyzed in FlowJo software (TreeStar, Ashland, OR). 
Treatment with proteolytic inhibitors 
Sorted, traversed HC-04 cells were treated at different time points pi with 
chemical inhibitors:  proteasomal inhibitor lactacystin (20 µM, Sigma); inhibitor of 
lysosomal acidification, chloroquine (100 µM, Sigma); autophagy inhibitor 10 µM 
spautin-1 (Cellagen Technology, San Diego, CA) for 16 h prior to sample collection.  
Statistical methods 
Statistical analyses were performed with GraphPad Prism 6 (GraphPad Software 
Inc., La Jolla, CA). Bar graphs display mean ±SE. One-way ANOVA was used to 
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compare more than two groups. Contingency tables with Chi-square or Fisher’s Exact 
Test were used to compare frequency distribution of patterns of CSP at different times or 
following proteolytic inhibitor treatment.  
2.3 Results 
2.3.1 Flow-cytometry based detection and sorting of traversed cells 
Traversed hepatocytes were identified by a flow-cytometry based membrane 
wounding assay adapted from previously described methods (Prudêncio et al. 2008). P. 
falciparum sporozoites were added to a monolayer of HC-04 cells in medium containing 
10,000 MW dextran conjugated to fluorescein, tetramethylrhodamine, or Alexa Fluor 647. 
At 2 h pi, there was a small background (0.307%) of dextran-positive cells noninfected 
cultures, 27.8% dextran uptake in Pf-infected cultures, and a near-complete return to 
background levels of dextran-positivity (2.45%) with the addition of Cytochalasin D, a 
chemical inhibitor of actin polymerization (Figure 2.1). We also used this strategy to 
separate nontraversed (dextran-, PI-) from traversed (dextran+, PI-) cells by fluorescence 
activated cell sorting (Figure 2.2). 
Though it is frequently used, questions remain regarding the interpretation of this 
assay, such as if the dextran enters upon sporozoite entry or exit, the significance of the 
range of fluorescence intensities observed, and whether or not dextran is taken up during 
invasion as well. It is thought that as the sporozoite breaches host the plasma membrane 
as it enters for traversal, producing a small hole in which the fluorescent dextran can 
enter, thus the percent of cells that take up dextran reflects the percent of cells that were 
traversed (Mota et al. 2001). An alternative assay quantifies traversal by measuring the 
release of calcein pre-loaded into cells, providing information about the frequency of cell 
 36 
wounding for an entire population (Coppi et al. 2007). While we speculate that the 
fluorescence intensity of dextran could be an indicator of the number of times a single 
cell was traversed, this has yet to be demonstrated. It is also unclear if productive 
sporozoite invasion leads to dextran uptake or not. Using HepG2/CD81 and HepG2, 
which are and are not permissive to productive invasion with P. yoelii, respectively, 
dextran was found in cells with sporozoites that had entered the cell without productive 
PV formation, but not those with PVs (Silvie et al. 2006). The investigators concluded 
that productive invasion does not result in dextran uptake. While P. yoelii is thought to be 
the most relevant surrogate rodent parasite for P. falciparum invasion of hepatocytes 
(March et al. 2013), it has yet to be demonstrated if P. falciparum invasion is 
accompanied by dextran-positivity. Due to the technical difficulty of distinguishing cells 
that have been only invaded from cells that have been invaded as well as traversed, we 






Figure 2-1. Flow cytometric detection of sporozoite traversal 
Representative example of flow cytometry-based detection of traversed cells. 
Cytochalasin D, an inhibitor of actin polymerization, was used to demonstrate that 
dextran uptake required active sporozoite motility and was not due to nonspecific 
wounding of the hepatocyte plasma membranes by other components present in 
sporozoite preparations. Bar graph summarizes same experiment in triplicate. * = 
significance following t-tests corrected for multiple testing.  
 
Figure 2-2. Fluorescence activated cell sorting of traversed cells 
Viable traversed cells were isolated by flow cytometry based cell sorting using dextran 
conjugated to different fluorophores in independent experiments. Gating is based on 
specific dextran uptake as shown in (Figure 2.1) in the viable, PI-negative cell population 
following exclusion of cell debris and cell “doublets” (data not shown). 
2.3.2 Traversed cells retain immunodominant antigen CSP in the absence 
of detectable EEFs  
Since sporozoites shed CSP during gliding motility, we asked whether CSP was 
shed into host cells during traversal. We looked for the presence of CSP by antibody-
based methods using monoclonal antibody 2A10, which recognizes the central repeat 
region.  
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We analyzed HC-04 cells infected with P. falciparum in the presence of dextran-
tetramethylrhodamine for the presence of CSP. A representative experiment is shown in 
Figure 2.3. Four hours pi, we detected CSP in 38.5% of dextran-positive cells after 
fixation and permeabilization, and in 9.05% of dextran-negative cells (Fig 2.3). We 
speculate that factors such as the amount of time spent by a sporozoite in a cell, and how 
large an opening it formed in the host plasma membrane, affected how much dextran and 
CSP were deposited.  
 
 
Figure 2-3. Flow-cytometric detection of CSP in traversed cells.  
CSP is detected in traversed (Dex+) cells by intracellular staining and flow cytometry 4 h 
pi. CSP-Alexa Fluor 647 staining is indicated within Dex- and Dex+ populations in 
unsorted, noninfected (top) and Pf-infected (bottom) cultures. Noninfected cultures 
incubated with dextran show low levels of spontaneous dextran uptake and absence of 
CSP-specific fluorescence. 
Visualization of intracellular CSP, as opposed to surface CSP, by microscopy has 
long been used to identify sporozoite-invaded cells (Renia et al. 1988). This method has 
recently been adapted as the basis for a flow cytometric determination of invasion as well 
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(Kaushansky et al. 2012). In the technique used by Kaushansky and colleagues, 2% of 
fixed, permeabilized HC-04 cells were CSP-positive. The investigators described this as a 
2% invasion rate, which significantly exceeds invasion efficiencies previously reported 
by many other investigators and our own findings (Dumoulin et. al., submitted): 0.066% 
for HC-04 cells, (Sattabongkot et al. 2006); 0.09% for HHS-102 cells, (Karnasuta et al. 
1995); and only slightly higher in primary human hepatocytes, 0.13%, (Mazier et al. 
1985). Thus, we sought to validate the proposed method (Kaushansky et al. 2012) by 
introducing additional parasite-specific markers. First, we stained live cells from P. 
falciparum – infected HC-04 cultures with 2A10 antibody conjugated to Alexa Fluor 488, 
to identify cells that had CSP on the surface. In this experiment, 14% of infected cultures 
retained dextran at 24h pi (Figure 2.4a). Next, we fixed and permeabilized these cells, 
and stained with 2A10-Alexa Fluor 647, to stain all CSP, including intracellular and 
surface, if any. In this representative experiment, 15% of cells were CSP-Alexa Fluor 647 
positive, and only 0.036% were CSP-Alexa Fluor 488 positive (Figure 2.4b), indicating 
that nearly all CSP was intracellular, and not on the surface of hepatocytes. Surface CSP 
is thought to be found on non-invaded cells over which sporozoites shed CSP during 
gliding motility. 
We then performed double staining of infected cultures with antibodies against 
both parasite-specific CSP and Hsp70. Only 0.099% of all hepatocytes were 
CSP+Hsp70+ (Figure 2.4c). We propose CSP+Hsp70+ to be  a more accurate measure of 
the percent of parasite-invaded cells than the detection of intracellular CSP alone, which 
reflects CSP shed in hepatocytes during sporozoite traversal (CSP+Hsp70-).  
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We address a technical limitation of this 3-color staining protocol. Alexa Fluor 
488 is emitted in the same fluorescent channel as parasite-expressed GFP. However, we 
observe that GFP expression in this parasite strain is weak and difficult to monitor in 
sporozoites, but increases with parasite replication. The earliest time point that we 
routinely observe parasite-encoded GFP by flow cytometry is 48 h pi. Therefore, the 
fluorescence signal emitted by cells stained with anti-CSP-Alexa Fluor 488 is most likely 
surface CSP, and not GFP. 
Altogether, we showed dextran-positive, traversed cells are enriched for CSP 
versus dextran-negative, non-traversed cells, as expected, since CSP is shed during 
traversal (Stewart, Michael J., Vanderberg 1988). Additionally, the distinction between 
CSP detected on the hepatocyte surface and detected intracellularly is insufficient to 
identify invaded cells. 
 
 
Figure 2-4. Co-detection of CSP and Hsp70 in traversed cells. 
 CSP retained by traversed cells 24 h pi is almost entirely intracellular. Upper panels - 
noninfected, lower panels – Pf infected cultures. Traversed cells gated as dextran-positive 
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predominantly PfHsp70-negative (c). Intracellular detection of surface and intracellular 
parasite antigens is described in Materials and Methods. 
2.3.3 Traversed cells remain viable and proliferate in vitro 
Since the hepatocyte plasma membrane is breached during traversal, it would not 
be surprising if these cells had poor viability, or deteriorated soon after. However, 
dextran+ HC-04 excluded cell impermeant dye propidium iodide (PI) (Figure 2.2), 
indicating they were viable at the time of analysis.  Sorted, traversed cells proliferate at 
an equal rate to nontraversed cells (data not shown), consistent with other reports that P. 
berghei infected and traversed HepG2 cells do not show signs of stress by the formation 
of stress granules (Hanson & Mair 2014). We hypothesized that the viability of traversed 
cells supports the possibility that they could present sporozoite antigen, namely CSP, for 
the duration of EEF development.  
2.3.4 Traversed cells retain CSP for at least 6 days pi in vitro 
After sorting traversed and nontraversed cells by FACS, we propagated them in 
vitro and collected cells daily to assess the amount of CSP retained. Cells were 
distributed uniformly into 24-well plates immediately following sorting (6 h pi), and one 
well was collected at each indicated time point. The same proportion of cell lysate 
obtained from cells recovered from each well was loaded onto SDS-PAGE gels. We 
observed that CSP was still detectable by immunoblot 6 days pi, the latest time point 
monitored (Figure 2.5a). CSP detected in traversed cell lysate migrated at the same size 
as sporozoite lysate, and in between cells transiently transfected to express the full length 
and N-terminal cleave products of CSP (Figure 2.5b).  
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We identified traversed cells as a source of at least one sporozoite- and liver-stage 
antigen, CSP. Other parasite proteins have been found in trails of gliding sporozoites, and 
we speculate they may be deposited in traversed cells as well (Mota et al. 2002). As CSP-
specific CD8+ T cells are important in the killing of infected hepatocytes, this raises the 
possibility for presentation of CSP-derived peptides by traversed cells to recruit and 
activate T cells in close proximity to infected cells, the desired target of cytotoxicity. We 
proceeded to further analyze the duration of CSP retention within traversed cells, its 
subcellular localization, and the proteolytic systems involved in its degradation. 
 
 
Figure 2-5. CSP detection in traversed cells over 6 days 
Sorted traversed cells were re-seeded, propagated and analyzed for presence of CSP by 
western blot at different time points pi. Migration of CSP retained in traversed 
hepatocytes on SDS-PAGE gels. (a) Time kinetic of CSP retention in traversed 
hepatocytes. Equal numbers of traversed cells sorted 4 h pi were re-seeded into each well 
of 24-well plate. Traversed cells were viable and proliferated until time of sample 
collection. Therefore, samples used for western blotting correspond to equal proportions 
of the total cellular content obtained from the individual well collected at indicated time 
point. Data from one representative experiment out of 3 performed are shown.  (b) HC-
04 cells ectopically expressing P. falciparum 3D7 CSP in its uncleaved (CSPfull) or 














































2.3.5 Retained CSP is detected in six different patterns of subcellular 
localization in traversed hepatocytes  
Since HC-04 cells expressed MHC class I, but not class II, on the cell surface, we 
next sought to determine if the CSP found in traversed cells resided in a compartment 
accessible to components of the MHC class I processing machinery. It is well established 
that cytoplasmic and nuclear proteins are the major source of peptide epitopes presented 
by MHC class I, whereas proteins residing in vacuolar endosomal/lysosomal 
compartments are usually presented on MHC class II (reviewed in Vyas et al. 2008). We 
fixed, permeabilized and stained sorted, traversed cells at 24, 48, and 72h pi with anti-
CSP, and visualized cells by fluorescence-widefield microscopy. We found varied 
subcellular localization of CSP in traversed cells, emerging as 6 distinct patterns of 
antibody-based staining (Figure 2.6A): 
 
Pattern 1) Homogenous puncta: similar sized puncta spread randomly throughout 
the cell 
Pattern 2) Heterogeneous puncta: variable size and/or focused localization 
Pattern 3) Single intracellular aggregate, “intracellular CSP body”: generally 
located perinuclear 
Pattern 4) Single extracellular aggregate tethered to plasma membrane, 
“extracellular CSP body” 
Pattern 5) Nuclear 
Pattern 6) Cytosolic 
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We performed experiments in nonsorted, infected cultures of cryopreserved 
primary human hepatocytes and observed similar patterns, validating the observations in 




Figure 2-6. Subcellular localization of CSP in traversed hepatocytes.  
Sorted, traversed cells were propagated on coverslips from 6 to 72 h pi. 
Immunofluorescence detection of CSP was performed at 24, 48 and 72 h pi. 
Representative images are derived from a total of eight independent experiments, 19 
cover slips and 174 individual cells. Each experiment utilized separate preparations of 
infected mosquitoes, isolation of sporozoites, cell sorting and immunostaining. (A) P. 
falciparum CSP is found in traversed HC-04 hepatocytes in six distinct staining patterns: 
(1) homogeneous puncta; (2) heterogeneous puncta; (3) large intracellular aggregates or 
“intracellular CSP bodies”; (4) large extracellular aggregates or “extracellular CSP 
bodies”; (5) nuclear; (6) diffuse cytoplasmic. (B) Six patterns of P. falciparum CSP 



















2.3.6 CSP bodies are distinct from developing EEFs 
Patterns 3 and 4 (Figure 2.6A) were large foci containing CSP that appear to be 
membrane-bound, with morphology similar to that of a parasitophorous vacuole (PV). 
Thus, we sought to determine if these structures contained developing EEFs or remnants 
of dead or dying parasites. We looked for localization of DAPI and Hsp70 to the CSP-
containing compartment, and found both to be absent (Figure 2.7). Positive control 
staining in Figures 2.7A,B show that a sporozoite and early PV contain DAPI and Hsp70, 
whereas the Pattern 4 “CSP body” in Fig. 2.7C only shows CSP-specific staining. 
Therefore, “CSP bodies” do not contain developing parasites. However, we cannot 
formally exclude the possibility that this compartment contains remnants of a dead EEF, 
and the CSP has a longer half-life than Hsp70 or the parasite DNA. Regardless of 
whether the “CSP body” originated from an intact EEF or not, the presence of CSP as a 
single parasite antigen in this pattern is of interest due to its potential as a source for 





Figure 2-7. "CSP bodies" are distinct from P. falciparum EEFs developing in human hepatocytes. 
Dense intracellular compartments containing CSP are devoid of markers characteristic for 
P. falciparum, DAPI and PfHsp70. Whereas parasites with morphology of sporozoite (A), 
and trophozoite (B) were stained positive for DAPI and PfHsp70, these markers were not 
detected in subcellular compartment containing CSP-bodies (Pattern 3) (C). Blue = DAPI, 
red = anti-PfCSP 2A10, green = anti-PfHsp70 4C9. Scale bars = 10 µM. 
2.3.7 Nuclear CSP is detected in the absence of an intranuclear EEF 
Reportedly, P. falciparum and P. yoelii EEFs can partially develop within the 
nucleus of non-permissive cell type HepG2 (Silvie et al. 2006), so we determined if the 
nuclear CSP (Pattern 5) we detected in traversed cells was, likewise, an early EEF. We 
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observed that CSP in the nucleus of traversed cells was distinct from intranuclear EEFs, 
as shown in Figure 2.8. We detected in the same field of view (1) a cell with a 
cytoplasmic sporozoite, which had detectable CSP, DAPI, and Hsp70 and (2) a cell with 
CSP in the nucleus, without Hsp70. Nuclear antigens are generally processed by the 
proteasome for MHC class I presentation (reviewed in (Neefjes et al. 2011)). Without 
evidence of sequestration by a PV, we speculated that nuclear CSP in traversed cells is 




Figure 2-8. Nuclear pattern of CSP in traversed cells is not associated with nuclear EEFs. 
CSP in hepatocyte nucleus (Pattern 5) is not accompanied by PfHsp70 detection. (A) Top 
micrograph shows two CSP-containing HC-04 cells found in same field of unsorted 
hepatocyte cultures. (B) Below, individual panels show detectable DAPI and PfHsp70 in 
cell 1 but not in cell 2, which contains CSP in the nucleus. Blue = DAPI, red = anti-










2.3.8 Subcellular localization of CSP fluxes over time, with CSP becoming 
increasingly aggregated 
When analyzing the localization of CSP in traversed HC-04 cells over time, a 
clear trend appeared: CSP tended to localize to increasingly large aggregates (Figure 2.9). 
CSP was predominantly found (40%) in homogenous puncta (Pattern 1) 24h pi. The 
frequency of this pattern declined to about 10% 48h pi and 2% at 72h pi. This decrease 
was paralleled by a rise in the frequency of cells with CSP in heterogeneous puncta 
(Pattern 2). Heterogeneous puncta were also prominent 24 h pi, increased slightly at 48 h 
pi, and returned to initial levels 72 h pi. Remarkably, both intra- and extracellular “CSP 
bodies” accumulated over time and were found in 12% and 15%, respectively, of all 
CSP-containing traversed cells at 72 h pi. Similar to CSP bodies, the frequency of cells 
with diffuse cytoplasmic CSP elevated from 2% at 24 h pi to 19% at 48 h, remaining 
stable through 72 hours. Finally, the nuclear pattern of CSP (Pattern 5), found in 
approximately 8% of traversed cells at 24 h pi, rapidly decreased and was undetectable at 
72 h pi. Thus, at least two patterns of CSP retention compatible with classical MHC class 
I antigen processing and presentation, cytoplasmic and nuclear, were found in nearly one 
third of CSP-containing traversed hepatocytes at 72 h pi, though the nature of other 
intracellular compartments containing the remaining CSP moieties was still undefined. 
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Figure 2-9. Dynamic changes of CSP subcellular localization in traversed HC-04. 
Percentages of cells bearing each of the six CSP patterns from all CSP-containing 
traversed cells analyzed at 24, 48 or 72 h pi., p < 0.0001 for comparison of the frequency 
distribution of CSP patterns across three time points by Chi-square and Fisher’s Test 
 
2.3.9 Proposed progression of CSP aggregation 
Drawing from the alteration of frequency with which each pattern is found over 
time, we speculated that CSP aggregates as illustrated in Figure 2.10. It appears that CSP 
transitions from Pattern 1 to 2 to 3 to 4, becoming increasingly aggregated as the cell 
deals with CSP as a misfolded protein, eventually expulsing it. The primary question of 
whether or not each of these pools of CSP is accessible to the proteasome for loading 
onto MHC class complexes was still unanswered. To try to understand the processes 
causing this progression, we co-stained traversed cells with antibodies specific for CSP 
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Figure 2-10. Proposed dynamic changes in patterns of retention and MHC class I presentation of 
CSP in hepatocytes traversed by P. falciparum sporozoites. 
 
Schematic of CSP Patterns 1 – 6. Red = CSP and CSP-derived MHC class I peptides. 
Green = class I peptides derived from self-antigens. Arrows represent proposed transition 
through patterns as CSP aggregates. We speculate that due to the complex, repetitive 
structure of CSP, it is recognized by the host cell as a misfolded protein, actively diverted 
into inclusion bodies in the lysosomal-autophagosomal pathway and either degraded 
intracellular or expulsed in the form of large aggregates. We further speculate that 
whereas “vesicular” Patterns 1, 2, and 3 may allow for at least some presentation of CSP 
epitopes on MHC class I via nonclassical, TAP-independent processing and presentation 
pathway, as previously described for other antigens (Del Val et al. 2011). Patterns 5 and 6 
will serve as a major source for CSP-derived MHC class I-restricted epitopes. We infer 
that Pattern 4 does not permit presentation of CSP by traversed hepatocytes, as this 
protein is no longer processed by the cell. Instead, we propose that these extracellular 
CSP aggregates may constitute a long-lived source of antigen for cross presentation by 
liver-resident professional antigen presenting cells, thus contributing to the induction 
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2.3.10 Subcellular compartments containing CSP contain ubiquitin, 
lysosomal and autophagic molecular markers 
We co-stained sorted, traversed HC-04 cells with a panel of antibodies specific 
for compartments associated with protein processing: lysosomal-associated membrane 
protein 1 (LAMP1), LC3B (a component of the autophagosomal membrane) (reviewed in 
(Barth et al. 2010)), p62 (involved in targeting ubiquitinylated substrates to the 
autophagosome for clearance of protein aggregates) (Pankiv et al. 2007), polyubiquitin 
(indicating proteins tagged for proteasomal or autophagosomal degradation such as 
aggregates of defective ribosomal products or other misfolded proteins (Wenger et al. 
2012)), early endosome marker EEA1 and late endosome marker Rab7. Representative 
images and the percent co-occurrence for each molecular marker within the selected CSP 
pattern are shown in Figure 2.11.  
CSP in homogeneous puncta (Pattern 1) co-localized frequently with 
polyubiquitin (38%) and Rab7 (39%), less frequently with LAMP1 (15%), LC3B (18%), 
and p62 (22%), but minimal co-occurrence was observed with EEA1, indicating that 
these CSP moieties are associated with lysosomal and autophagosomal compartments, 
and not early endosomes (Figure 2.11A).  
CSP in heterogeneous puncta (Pattern 2) was almost completely associated with 
polyubiquitin (98%) and LC3B (73%) within vacuoles visible by phase contrast 
microscopy, suggesting its interaction with a different compartment than homogenous 
puncta (Figure 2.11B). Less frequently, Pattern 2 CSP co-localized with LAMP1 (15%) 
and Rab7 (33%).  
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Similarly to CSP in Pattern 2, a substantial portion of intracellular CSP bodies 
(Pattern 3) co-localized with LC3B (34%) (Figure 2.11C). However, dissimilar to 
punctate CSP, CSP bodies were not associated with p62. This suggests that autophagy-
related compartments containing CSP in Pattern 2 have a distinct molecular composition 
from those characterized as Pattern 3.  This observation was further supported by the 
higher co-localization of intracellular CSP bodies with Rab7 (94%). Rab7 is important in 
the formation of large, late autophagic compartments (Jäger et al. 2004), fitting our 
proposed model of a sequential progression from small puncta to large, aggregate CSP 
bodies. 
When CSP bodies appeared to transition to a dense, membrane-bound structure 
externally tethered to a host cell visible by phase contrast (Pattern 4), the molecular 
composition of the CSP-containing compartment also shifted (Figure 2.11D). Though 
extracellular CSP bodies still contained the late endosome marker Rab7, these aggregates 
largely lost their association with LAMP1. Because Pattern 4 occurred relatively 
infrequently, we were unable to detect it in any p62- or LC3B- stained samples.  Patterns 
5 and 6 were not analyzed in this manner because none of these molecular markers 
possess a diffuse cytoplasmic or nuclear distribution. 
Altogether, our data demonstrate that the close association of CSP with these 
organellar markers shifted along with the dynamic localization patterns of CSP. We 
speculated that CSP retained in each compartment might have variable susceptibility to 
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Figure 2-11. Characterization of subcellular compartments retaining CSP in traversed cells.  
Co-occurrence of CSP with markers specific for early endosomal (EEA1), late endosomal 
(Rab7), lysosomal (LAMP1), autophagy-related (LC3and p62) compartments and poly-
ubiquitin species was assessed by immunofluorescence microscopy. Representative 
images are shown for intracellular CSP found in pattern 1 (A), 2 (B) 3 (C) and 4 (D). 
Scale bars = 10 µM. Degree of CSP co-occurrence with each marker (described in 
Materials and Methods) indicated as percentages of total CSP are shown on each image. 
Blue = DAPI, red = CSP, green = marker, white = (co-occurrence of CSP and 
marker)/total CSP. 
 



























2.3.11 Proteolytic processing of CSP in traversed cells is impaired by 
chemical inhibitors of the proteasome, lysosome, and autophagy 
Three major cellular proteolytic machineries, the proteasome, lysosome and 
autophagy, are implicated in the generation of peptide ligands for antigen presentation. 
Whereas the proteasome and, for some antigens, autophagy-related proteolysis produce 
CTL epitopes presented on MHC class I, the deviation of antigens to the lysosome likely 
withdraws them from classical MHC class I presentation pathway (reviewed in 
Villadangos & Schnorrer 2007). We investigated if specific inhibition of these proteolytic 
pathways would interfere with the stability and/or intracellular distribution of CSP 
retained in traversed cells.  
Selective chemical inhibition of all three proteolytic pathways, the proteasome 
(lactacystin), lysosome (chloroquine) or autophagy (spautin-1) from 8-24 and 32-48h pi 
each resulted in an accumulation of CSP in traversed cells (Figure 2.12A), indicating that 
all three proteolytic systems regulate the degradation and/or intracellular retention of CSP 
during the first two days post traversal. On the other hand, only inhibition of the 
lysosome and autophagosomal pathways, and not the proteasome, led to CSP 
accumulation from 56 to 72 h pi, suggesting that proteasomes do not play a major role 
after two days post traversal (Figure 2.12A). At this latest time point, larger aggregates 
(Patterns 3 and 4) are more predominant than the small puncta observed at 24h pi. This 
suggests that “CSP bodies” are not susceptible to proteasomal degradation. In contrast, 
inhibition of either the lysosome or autophagy recapitulated effects seen at earlier time 
points, indicating that lysosomal and autophagosomal proteolysis are active regulators of 
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CSP turnover in traversed cells during the first three days following infection (Figure 
2.12A).  
2.3.12 Distinct cellular proteolytic machineries differentially regulate each 
CSP-containing compartment 
Next, we asked whether the accumulation of CSP following specific inhibition of 
proteolysis was accompanied by changes in its subcellular distribution. We monitored the 
frequency of each CSP pattern following specific inhibition of the proteasomal, 
lysosomal, or autophagosomal processing pathways.  
Inhibition of the proteasome at 24 h pi resulted in increased frequencies of cells 
bearing cytoplasmic diffuse CSP (Pattern 6), probably reflecting the inhibition of 
otherwise rapid proteasome-dependent turnover of these CSP moieties, like other 
cytoplasmic antigens (Figure 2.12B). Unexpectedly, inhibition of the lysosome and 
autophagy also led to an increased frequency of cells containing cytoplasmic CSP. This 
could suggest that lysosomal-autophagosomal systems degrade cytoplasmic CSP as well.  
Alternatively, inhibitor-induced perturbance in other vesicular compartments retaining 
CSP and regulated by these proteolytic systems, results in the release of CSP into the 
cytosol. In agreement with the latter hypothesis, we observed decreased frequencies of 
traversed cells with Pattern 1 CSP when treated with lactacystin, chloroquine and 
spautin-1 (Figure 2.12B).  
Surprisingly, at 48 and 72 h pi, chloroquine did not significantly alter frequencies 
of cells with diffuse cytoplasmic CSP, while inhibition of the proteasome and autophagy 
decreased the frequency of this cell population (Figure 2.12B). This observation is 
counterintuitive, as proteasomal inhibition usually results in accumulation of cytosolic 
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antigens. It is possible that inhibition of the proteasome or autophagy at late time points 
post traversal sequesters cytoplasmic CSP molecules into other compartments, the 
integrity or activity of which depend on these proteolytic machineries. This hypothesis is 
supported by the increased frequencies of cells with heterogeneous punctate staining 
(Pattern 2) observed in response to proteasomal inhibition at 48 and 72 h pi and 
accumulation of cells bearing intra- or extracellular “CSP bodies” in cultures treated with 
the autophagy inhibitor spautin-1 at 48 and 72 h pi (Figure 2.13B). 
Overall, the patterns of CSP found in inhibitor treated cells varied significantly 
from the media control during 8-24h and 56-72h, but not from 32 – 48h pi. (Figure 
2.12B) This could suggest that during this time period, CSP was the most stable, or 
subject to the slowest degradation. The greatest variation in subcellular localization of 
CSP following inhibitor treatment was seen at 72h pi.  
In conclusion, all three major proteolytic systems, lysosome, proteasome and 
autophagy, simultaneously regulate turnover of CSP in traversed cells. As the latter two 
are capable of generating MHC class I peptide ligands, we propose that a portion of CSP 
is available for classical MHC class I presentation in traversed cells throughout the first 





Figure 2-12. Inhibitors of proteasome, lysosome and autophagy differentially regulate processing of 
CSP residing in distinct subcellular compartments. 
 (A) Sorted traversed cells were treated with the inhibitors of the proteasome (lactacystin), 
lysosome (chloroquine) and autophagy (spautin-1) during 16 h prior to 24, 48 and 72 h pi 
and CSP was detected by western blot. Accumulation of ubiquitin species and detection 
of 2 forms of LC3B protein were used to confirm the efficacy and specificity of 
treatments. Actin was used as a sample loading control. (B) Distribution of intracellular 
CSP patterns in response to inhibition of proteasome, lysosome and autophagy; 175 – 200 
A 
B 
3: intracellular “CSP bodies” 
2: heterogenous puncta 
1: homogenous puncta 
6: cytoplasmic 
5: nuclear 
4: extracellular “CSP bodies” 
* ns **** 
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traversed cells containing CSP were analyzed for each inhibitor treatment in three to six 
independent experiments. Treatments with inhibitors are described in Materials and 
Methods.  Statistical comparisons were performed between treatments within each time 
point using Fisher’s Exact Test. ns = not significant, * =  p < 0.05, **** = p < 0.0001. 
2.4 Discussion 
It has previously been described that sporozoites shed CSP apically during gliding 
motility (Stewart, Michael J., Vanderberg 1988; Stewart & Vanderberg 1991). Hence, we 
investigated the deposition of CSP into hepatocytes during the second type of sporozoite 
motility, cell traversal. We documented for the first time that traversed cells retain CSP 
shed from sporozoites for an extended period of time, up to six days (Figure 2.5). This 
suggests that CSP from traversed hepatocytes could be available for presentation to T 
lymphocytes and potentially recruit and/or activate effector CD8+ T cells to the region 
proximal to infected cells throughout the duration of EEF development.  
As CSP is transcribed and protein is present in EEFs for at least five days (Sacci 
et al. 2006; Mikolajczak et al. 2011), it is theoretically possible that EEFs could remain 
targets of CSP-specific cytotoxicity throughout this time. While CSP is sequestered into 
the PV of developing EEFs, studies have shown that it is released by sporozoites prior to 
PV formation (Hügel et al. 1996) or exported to the hepatocyte cytoplasm (Singh et al. 
2007) and that EEFs directly activate CSP-specific CTLs in an HLA-restricted, 
proteasome dependent manner (Bongfen et al. 2007). Therefore, if CSP could be 
presented from traversed cells located proximally to invaded cells, we speculate traversed 
hepatocytes may play a role in controlling infection by recruiting and/or activating CSP-
specific CTLs. 
To address whether or not CSP in traversed cells has the potential to be presented 
by MHC class I, we analyzed the subcellular localization and machinery involved in its 
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turnover. Classical MHC class I presentation requires cytoplasmic or nuclear localization 
for access to proteasomal processing. Only a minority of CSP in traversed cells (10-20% 
of CSP-positive cells) visualized by immune fluorescence microscopy was cytoplasmic 
or nuclear (Figure 2.9), and total CSP amounts detected by immunoblot were only 
affected by proteasomal inhibition 24 and 48h pi, but not 72h pi (Figure 2.12). This 
suggests that only a small amount of CSP in traversed cells is available for MHC class I 
presentation. However, it is possible that the infrequency of cells containing Pattern 6, 
cytoplasmic CSP, could be due to the fact that the cytoplasm is an effective proteolytic 
compartment, and these pools of CSP are turned over immediately upon release into the 
cytoplasm. Furthermore, there is increasing evidence for the presentation of 
lysosomal/endocytic antigens by MHC class I through non-canonical, TAP-independent 
pathways utilizing cathepsins (reviewed in Del Val et al. 2011).  Thus, we speculate that 
more traversed hepatocytes than those in which we detected CSP in the cytoplasm or 
nucleus should have the capacity to present CSP. 
In investigating the subcellular localization of CSP deposited in traversed cells, 
we uncovered a novel phenomenon in the turnover of this parasite antigen: its 
accumulation in large, stable aggregates. It is common for misfolded and aggregated host 
proteins to proceed through a sequestration and degradation process, the formation of 
aggresomes and aggresomes-like induced structures (ALIS), that appears somewhat 
similar to our observations (Szeto et al. 2006; Johnston et al. 1998). This aggregation 
could possibly serve both a benefit and detriment to the host. We speculate that Pattern 4 
extracellular “CSP bodies,” may persist for an extended period of time in the observed 
membrane-bound extracellular compartments. If phagocytosed by dendritic cells, 
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extracellular “CSP bodies” could serve as a long-term reservoir of malaria antigen that is 
essential for maintenance of memory responses (Cockburn et al. 2010).  Alternatively, if 
not phagocytosed, then this pool of expulsed CSP could serve as a means to evade 
presentation. In our experimental system, we were unable to investigate these scenarios 
further. 
Altogether, these studies revealed new findings about the deposition and retention 
of CSP antigen in its natural, post-translationally modified manner by the sporozoite, into 
the host cell type required for completion of the exo-erythrocytic phase. We found this 
antigen is retained for an extended period of time with dynamic subcellular localization 
and is subject to processing by multiple proteolytic systems. These data establish a 
foundation for investigating the role of traversed hepatocytes as targets in the CSP-




Chapter 3. INDUCTION OF CD8+ T CELL RESPONSES 
AGAINST TRAVERSED CELLS: RECOGNITION, 
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The liver stage of malaria is an ideal vaccine target because inhibiting infection at 
liver stage will prevent both clinical malaria and transmission. Furthermore, it is a 
“practical” target as 1) low parasite numbers in the liver represent a “bottleneck” of 
Plasmodium infection and 2) the immune system is able to abrogate infection through 
major histocompatibility complex (MHC) class I-restricted CD8+ cytotoxic T cell (CTL) 
recognition of infected hepatocytes (reviewed in (Van Braeckel-Budimir & Harty 2014; 
Tse et al. 2011)).  
Plasmodium EEFs develop within the PV, a controlled environment sequestered 
from the host cytosol in which the parasite can avoid innate immune signals and 
proteolytic machinery of the host. The double plasma membrane of the PV is thought to 
strictly regulate trafficking between the parasite compartment and host cytosol, allowing 
only for import and export of molecules beneficial for parasite growth (reviewed in 
(Ingmundson et al. 2014)). Parasite proteins containing Plasmodium export elements 
(PEXEL) RxLxE, including CSP, liver-stage antigen 3 (LSA-3), IBIS1 and PFB0105c 
are believed to be exported outside the PV (Marti et al. 2004; Singh et al. 2007; 
Ingmundson et al. 2012; Siau et al. 2008). While there is evidence that several liver stage 
antigens may be exported to the cytosol and, therefore, may become targets for CTL 
responses (Plebanski, Aidoo, et al. 1997; Aidoo et al. 2000; Bongfen et al. 2007; Toure-
Balde et al. 2009; Sedegah et al. 2013), this process is still under scrutiny (Cockburn et al. 
2011). Nonetheless, the requirement for MHC class I-restricted CTL responses against 
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liver stage antigens is well-documented, as is the case with other intravacuolar bacterial 
and protozoan infections (reviewed in (Blanchard & Shastri 2010). 
As discussed in Chapter 2, CSP, an important target of protective CD8+ T cell 
responses following vaccination, was retained in hepatocytes traversed by P. falciparum 
sporozoites. Furthermore, CSP detected in traversed cells was long-lived, retained in 
several, dynamic subcellular compartments, and was subject to degradation by multiple 
cellular proteolytic machineries, including the proteasome, which is important for MHC 
class I presentation. Importantly, traversed cells remained viable for several days.  
It was still not clear, however, whether breaching of the hepatocyte plasma 
membrane and release of the cellular content into the extracellular milieu (Carrolo et al. 
2003; Leirião et al. 2005) affects the ability of traversed hepatocytes to effectively 
stimulate MHC class I-restricted CTL responses. In particular, it is not known whether or 
not traversed hepatocytes can sufficiently activate CD8+ T cells to execute the full array 
of T cell effector functions, including cytokine secretion, cytotoxic granule release, and 
cell division. It is also unknown if the process of traversal affects the immunogenicity of 
neighboring, nontraversed hepatocytes. 
We speculated that this CSP retained in traversed cells might serve as another 
source, in addition to infected hepatocytes, of presented peptides to induce CTL 
responses. CSP induces both humoral and cellular immune responses in naturally infected 
and vaccinated hosts, including the well-studied CD8+ CTL-mediated control of malaria 
liver stages (reviewed in Hafalla et al. 2011).  Therefore, identification of antigen 
presenting cells capable of presenting liver stage antigens on MHC class I to CD8+ T 
 69 
cells remains an important goal. Thus, we sought to determine if traversed cells could 
present CSP to trigger effector functions of CTLs. 
Here, we utilized two experimental models to 1) assess T cell activation as a 
measure of the overall stimulatory capacity of the hepatocyte while bypassing 
endogenous antigen presentation and 2) specifically determine the ability of traversed 
hepatocytes to endogenously process and present a CTL epitope derived from the C-
terminus of CSP. We performed an extensive comparative analysis of the capacity of 
traversed, non-traversed and non-infected hepatocytes to serve as stimulators of MHC-
class I-restricted CTL responses. Our data demonstrate that traversed, non-traversed and 
non-infected hepatocytes had similar abilities to trigger the full array of T cell activation 
events, suggesting that effective parasite-specific CTL responses may take place in close 
proximity to hepatocytes harboring developing EEFs. Additionally, traversed cells 
specifically induced IFNγ cytokine production by CSP-specific human CTLs. Activation 
of these CTLs by infected cultures of HC-04 cells limited the development of P. 
falciparum EEFs. 
3.2 Materials and Methods 
Surface staining and flow cytometry of HC-04 cells 
Traversed and nontraversed HC-04 cells were incubated with antibodies against 
HLA-ABC, CD54 (BD, Franklin Lakes, NJ), HLA-E (eBioscience, San Diego, CA) or 
relevant isotype control antibodies directly conjugated to fluorophores. Data were 
acquired on FACSCaliburTM (BD) using CellQuest Pro software (BD).  
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CSP-coding DNA plasmids  
Expression vectors coding for two forms of CSP, CSPfull and N-terminal 
cleavage product CSPshort were generated by Elian Rakhmanaliev and Jinxia Ma 
(described in detail in (Ma et al. 2013)). Plasmids were utilized by for transient ectopic 
expression of CSP described below. 
The pVITRO2-neo-mcs (InvivoGen, CA, USA) contains two separate multiple 
cloning sites and allows the ubiquitous and constitutive co-expression of two genes of 
interest. Sequence encoding mouse CD8α was PCR amplified and inserted into one of the 
cloning sites. Surface expression of mouse CD8α serves as a heterologous surface marker 
of transfection efficiency in human cells. Sequences coding for either “full” or “short” 
length CSP from the P. falciparum 3D7 strain were cloned into the second cloning site. 
The P. falciparum CSPshort protein corresponds to the mature form of CSP produced by 
proteolytic cleavage of full length CSP during parasite interaction with the host cell 
plasma membrane (Coppi et al. 2005).  
Transient transfection with plasmids encoding P. falciparum CSP 
Adapted from (Ma et al. 2013). 
HC-04 cells were transfected with pVITRO2-CD8, pVITRO2-CD8/CSPfl, 
pVITRO2-CD8/CSPsh plasmids using Lipofectamine LTX (Life Technologies, Grand 
Island, NY). Expression of CSP was detected either by western blot in transfected cells at 
24 h post transfection or by immunofluorescence using CSP-specific mouse monoclonal 
antibody 2A10 (kind gift of Dr. F. Zavala, JHMRI, JHU). Beta actin-specific antibody 
AC15 (Sigma-Aldrich, St. Louis, MO) was used to verify equal loading of cell lysates. 
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Blots were developed using anti-mouse IgG-HRP (GE Healthcare, Pittsburgh, PA) and 
Super Signal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA). 
Twenty four and 48 h post-transfection, surface expression of mouse CD8α was 
assessed by staining with anti-mouse CD8α-RPE or IgG2b-RPE isotype control antibody 
(Invitrogen, Grand Island, NY) and MHC class I expression was assessed in CD8α+ cell 
populations as described above. Data acquisition was performed using FACSCaliburTM 
(BD Biosciences, San Jose, CA). To monitor MHC class I pathway and its 
responsiveness to pro-inflammatory cytokines in CSP transfected cells, hepatocytes were 
sorted by MoFlo Cell Sorter (Beckman Coulter, Indianapolis, IN) 24 h post-transfection, 
treated with AS or left untreated (as described above) for additional 24 h and real-time 
PCR analysis was performed for HLA-A heavy chain, β2m and TAP1 genes at 48 h post-
transfection. In parallel, class I heavy chain expression was assessed by western blot 
using specific rabbit polyclonal antibody (kind gift of Dr. H. Ploegh). 
Analysis of CTL activation by flow cytometry 
A CD8+ HLA-A*0201 -restricted human cytotoxic T lymphocyte (CTL) clone 
LF8, specific for EBV BMFL1 (280-288) CTL epitope GLCTLVAML (GLC) was 
generated as previously described (Levitsky et al. 1998) and used to assess T cell 
activation induced by HLA-A*0201-positive HC-04 cells pre-pulsed with the synthetic 
GLC peptide. HLA-A*0201 -specific allogeneic CD8+ CTL clone was used to evaluate 
its activation by HC-04 cells and primary HLA A2-positive human hepatocytes.  
BK-B5 CD8+ human CTL clone specific for an EBV EBNA4 (416-424) epitope 
IVTDFSVIK (IVT) (Levitsky et al. 1998) was used to evaluate the bystander effect of 
LF8 clone activation on traversed HC-04 cells. Hepatocytes were separated into traversed 
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and nontraversed populations at 2 h pi and pre-incubated with GLC peptide at 
concentration of 10-6 M or 10-8 M for 1 h followed by unbound peptide removal by 
washing.  Peptide-pulsed hepatocytes were co-cultured with CTLs at 3:1 CTL-to-
hepatocyte ratio for 4 h in complete medium containing Golgi Plug (BD Biosciences, San 
Jose, CA) followed by the concomitant surface staining with CD8-specific mouse 
monoclonal antibody conjugated to Pacific Blue and one of the following mouse 
monoclonal antibodies: anti-CD25, anti-CD69 or anti-PD-L1, all conjugated to 
phycoerythrin (PE). Cells were washed, fixed and permeabilized using Cytofix/Cytoperm 
(BD Biosciences, San Jose, CA) and incubated with one of the following antibodies: anti-
IL-2, anti-IFNγ or anti-TNFα, all conjugated to allophycocyanin (APC). Relevant IgG1 
isotype control antibodies, conjugated to PE or APC were used. All antibodies were 
obtained from BD Biosciences (San Jose, CA). Samples were acquired with a LSR II 
flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star, Inc., 
Ashland, OR). 
Multiplex cytokine detection 
For cytokine detection in the supernatants of activated T cells, CTL clone LF8 
was stimulated with HC-04 cells either not exposed to sporozoites (“uninfected”), or 
sorted Pf traversed or nontraversed cells, pulsed with exogenous cognate peptide as 
described above. CTLs (105) were stimulated with hepatocytes (1:1 ratio) at 30 h pi and 
supernatants were collected after 16 h of co-incubation, aliquoted and stored at -80C prior 
to analysis using Meso Scale Discovery Proinflammatory Panel 1 V-PLEX kit (Rockville, 
MD) and on Meso Scale Discovery SECTOR Imager 2400 following manufacturer’s 
protocols (Johns Hopkins School of Public Health Flow Cytometry Core Facility). 
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T cell degranulation assays 
HC-04 cells, either uninfected or separated into traversed and nontraversed 
populations 2 h pi, were pre-pulsed with GLC peptide at 24 h pi and co-incubated with 
LF8 CTLs at 1:3 T cell-to-hepatocyte ratio for 4 h in the presence of anti-CD107-PeCy5 
antibody or IgG1-PeCy5 isotype control antibody. Cells not pulsed with peptide were 
used as stimulators to determine the basal levels of exocytosis in CTLs. Samples were 
acquired with a LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo 
software (Tree Star, Inc., Ashland, OR). 
T cell proliferation assays 
LF8 CTLs were labeled with carboxyfluorescein diacetate succinimidyl ester, 
CFSE, (Life Technologies, Grand Island, NY) according to the manufacturer’s protocol 
and incubated with noninfected, nontraversed or Pf traversed HC-04 cells pre-pulsed with 
GLC peptide at 10-6 M or 10-8 M concentration. CFSE fluorescence was measured by 
flow cytometry in the CD8+ cell population at day 5 post triggering. CFSE fluorescence 
intensity of nonstimulated cells was used as a control for basal proliferation of T cells. 
Stimulations were performed in triplicate cultures.  
Analysis of endogenous CSP presentation by traversed cells 
Human CTLs specific for HLA-A*0201 restricted epitope PfCSP327-335 
(YLNKIQNSL) previously described (Bonelo et al. 2000) were generously provided by 
G. Corradin.  Custom Class I MHC tetramer for this epitope was kindly provided by the 
NIH Tetramer Core Facility (Emory University, Atlanta, GA). CTLs were stimulated by 
HC-04 cells either sorted (into traversed and nontraversed populations) from cultures 
infected with P. falciparum sporozoites, or unsorted infected and noninfected cultures. 
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HC-04 cells pulsed with exogenous PfCSP327-335 peptide (10-6 M) were used as a positive 
control. CTL activation was measured by the Miltenyi IFNγ Secretion Assay (Miltenyi 
Biotec Inc., San Diego, CA) following a 3 h stimulation according to manufacturer’s 
protocols. 
3.3 Results 
3.3.1 Immune surface phenotype is unaltered in traversed hepatocytes 
Pathogens alter MHC class I antigen presentation via multiple mechanisms 
leading to immune escape from CTL-mediated surveillance by downregulation of MHC 
class I complexes or induction of inhibitory HLA-E and HLA-G molecules (Abele and 
Tampe, 2011; Amiot et al., 2014; Basta and Bennink, 2003; Sullivan et al., 2008). We 
found that total levels of assembled MHC class I complexes on sorted, traversed 
hepatocytes, as measured by staining with HLA-A, B, C-specific antibodies, were similar 
to that on nontraversed cells at during at least the first 72 h pi with P. falciparum 
sporozoites (Figure 3.1). While marginal constitutive expression of HLA-E was observed 
in HC-04 cells, it was not altered by sporozoite traversal. Interestingly, ICAM-1, an 
essential component of the immunological synapse on antigen presenting cells (reviewed 
in (Thauland and Parker, 2010)) was more highly expressed on traversed hepatocytes, at 
least up to 72 h pi (Figure 3.1). The same trends were observed in HC-04 cells traversed 
by P. berghei (data not shown). HLA-G and HLA-DR,DP,DQ expression were not 
detected in neither noninfected nor infected cell cultures (data not shown). In summary, 
the cell surface phenotype of hepatocytes traversed with P. falciparum sporozoites is 




Figure 3-1. Traversed hepatocytes maintain expression of MHC class I and ICAM-1. 
Surface expression of total HLA class I, HLA-E and ICAM-1 was detected by 
immunostaining and flow cytometry on sorted traversed and nontraversed HC-04 at 
indicated times pi, as described in Materials and Methods. One representative experiment 
is shown. Numbers indicate geoMFI of cells stained with isotype control antibody 
(shaded histograms) or indicated specific antibody (open histograms). Data are 
representative of three independent experiments.  
 
3.3.2 Transient ectopic expression of CSP does not interfere with steady-
state or cytokine-induced expression of MHC class I molecules 
Data generated by S. Trop, published in (Ma et al. 2013) 
Upregulation of MHC class I and II expression by APCs in response to pro-
inflammatory cytokines is critical in orchestrating efficient immune responses against 
infections. Many pathogens subvert host immune surveillance by interfering with 
cytokine signaling (reviewed in (Alto & Orth 2012)). CSP, which is found in traversed 
cells (Chapter 2), has been shown to inhibit TNFα-induced translocation of NF-κB into 
the nucleus of HepG2 or HeLa cells, thereby preventing transcription of NF-κB 
responsive genes (Singh et al. 2007). These results prompted us to investigate whether 
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CSP expression alone could be sufficient to inhibit the inducible expression of genes 
controlling antigen processing and presentation. While we did not observe changes in 
surface expression of MHC class I in traversed cells retaining CSP deposited by 
sporozoites (Figure 3.1), we investigated if the ectopic expression of CSP, which yields 
different subcellular localization and quantities of protein, may have an effect on 
cytokine responsiveness.  
To examine the effect of CSP on MHC class I expression, we ectopically 
expressed the two major forms of P. falciparum CSP: the full length protein (CSPfl) and 
its truncated, “mature” form (CSPsh) that results from proteolytic cleavage during 
sporozoite interaction with host hepatocyte plasma membrane (Coppi et al. 2005) (Figure 
3.2A, B). CSP expression was driven from a bicistronic plasmid vector also encoding 
surface protein mouse CD8α (mCD8α), which served as a marker for transfection, 
allowing flow-cytometric detection and sorting of live CSP+ cells. HC-04 cells 
expressing mCD8α alone (vector control) or co-expressing with CSPfl or CSPsh were 
isolated 24 h after transfection or directly detected using immunostaining and flow 
cytometry  (Figure 3.2). 
In the course of natural immune responses, hepatocytes are likely to be exposed to 
a plethora of cytokines produced by activated T cells. Therefore, we assessed potential 
modulation of MHC class I machinery in HC-04 transfected with either mCD8α vector 
control, CSPfl, or CSPsh plasmids after treatment with recombinant TNFα and IFNγ or 
with supernatant collected from activated human CTLs (“activated supernatant”). Neither 
CSPfl nor CSPsh expression affected the steady state nor cytokine-induced mRNA levels 
of MHC class I heavy chain, β2M, or TAP1 24 h post-transfection (Figure 3.2C). In line 
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with this observation, surface expression of MHC class I was also unaltered by CSP 
expression under the same treatment conditions (Figure 3.2D, E). Likewise, expression 
levels of MHC class I heavy chain assessed by immunoblotting of total cell lysates were 
comparable between sorted CSP- and vector-transfected HC-04 cells (Figure 3.2F). 
Collectively, these results indicate that plasmid-driven expression of CSP does not 
interfere with the antigen presenting machinery in HC-04 human hepatocytes, contrary to 
the reports of Singh and colleagues (Singh et al. 2007). In conclusion, using two 
independent experimental models: (a) traversed cells retaining CSP deposited by 
sporozoites and (b) cells ectopically overexpressing CSP outside of the context of 
Plasmodium infection, we consistently demonstrated that CSP-containing hepatocytes 





Figure 3-2. CSP does not alter steady-state of induction of MHC class I 
(A) Expression of the full length (CSPf.l.) or mature “short” (CSPsh) form of P. 
falciparum CSP was detected by western blot 24 h post-transfection of HC-04 cells. (B) 
Cellular distribution of full length CSP 24 h post-transfection was visualized with a CSP-
specific antibody (green) and immunofluorescence microscopy. Nuclei were stained with 
DAPI (blue). Arrows indicate transfected cells. (C) Real-time PCR analysis of MHC 
class I heavy chain, β2-microglobulin and TAP1 gene expression in cells transiently 
expressing P. falciparum CSP. HC-04 cells transfected with the control vector plasmid or 
plasmid encoding either full length or short CSP were treated with AS (10% v/v) 4 h 
post-transfection or left untreated. Transfected cells were isolated 24 h later based on 
surface expression of mouse CD8α. Mean ± SD of the assay triplicates. All p* <0.0002 
and indicate differences between control and AS-treated samples. (D) Percentages of 
cells transiently expressing CSP were identified by CD8α co-expression (upper panels) 
and MHC class I was assessed by flow cytometry (lower panel, light gray histograms - 
isotype control, dark gray histogram - MHC class I specific antibody). A proportion of 
cells exposed to either AS (10% v/v) or a mixture of recombinant TNFα and IFNγ at 24 h 
post-transfection was further assessed for MHC class I expression at 48 h (light gray 
histograms - isotype control antibody, dark gray histogram - MHC class I in untreated 
cultures, solid line histogram – cultures treated with recombinant cytokines, dotted line 
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histogram – cultures treated with AS). Data from one representative experiment. (E) The 
means ± SD of MFI for specific MHC class I staining obtained in 3 independent 
experiments. All p* <0.0001 and indicated differences between control and treated 
samples. (F) Expression of MHC class I heavy chain (HC) in total cell lysates of HC-04 
cells transfected with CSP-expressing plasmids was assessed by western blot. Treatment 
with AS was done as described for D. 
3.3.3 Direct stimulation with traversed cells triggers activation of CD8+ T 
cells similarly to nontraversed cells 
It is generally accepted that the full program of CD8+T cell activation includes 
cytokine secretion, rearrangement of cell surface antigens at the immunological synapse, 
release of cytotoxic granules, and cell proliferation (reviewed in (Suni et al. 2005)). Next, 
we comprehensively assessed the ability of traversed cells to trigger activation of CTLs. 
Traversed cells induce cytokine secretion from specific CD8+ T cells 
First, we analyzed cytokine production in effector CTLs by two methods: 
intracellular staining, to measure numbers of responding cells, and multiplex cytokine 
detection in supernatants, revealing the total amount of multiple cytokines secreted from 
an entire culture of effector T cells.  
Upon activation of GLC-specific CTL line LF8 with peptide-pulsed nontraversed 
or traversed HC-04 cells, no differences in the number of cells producing IFNγ, TNFα or 
IL-2 or MFI were detected by intracellular staining and flow cytometry, neither at 6 nor 
at 24 h pi (Figure 3.3A, B, C). Furthermore, sporozoite-exposed HC-04 populations 
(separated into nontraversed and traversed) did not differ in their stimulatory capacity 
from cells not exposed to sporozoites (designated as “non-infected”). These findings were 
reproducible with an allogeneic HLA-A*02-specific CTL clone as a responder (Figure 
3.4A), as well as with HC-04 cells traversed with P. berghei sporozoites (data not shown). 
Taken together, these data indicate that traversed hepatocytes can stimulate cytokine 
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secretion from CTLs as efficiently as nontraversed or noninfected hepatocytes, 




Figure 3-3. Activation of peptide-specific CTLs by traversed and nontraversed hepatocytes pulsed 
with GLC peptide 
Cell sorting was done 2 h pi and hepatocytes were used as stimulators at 6 and 24 h pi. 
Intracellular IFNγ, TNFα and IL-2 cytokine detection in GLC peptide-specific CTL clone 






























































































































































LF8 was performed after 4h of co-culture, as described in Materials and Methods. (A) 
Representative histograms are shown. Shaded histograms define isotype control staining 
intensity and outline gating strategy. Numbers are percentages of cells with high 
cytokine-specific fluorescence.  (B) Summary of data obtained from three independent 
cultures analyzed for each time point and the cytokine. ns, no significant differences were 
observed comparing all groups by ANOVA (C)  MFI, mean fluorescence intensity for 
one representative experiment of 3 performed is shown. ns, no statistical differences were 
observed comparing groups within each cytokine by ANOVA. 
 
 
Figure 3-4. Intracellular cytokine detection in HLA-A*02-specific allogeneic T cells 
Allogeneic HLA-A*02-specific T cells were activated on traversed and nontraversed HC-
04 cells 24 h post infection. Gating strategy and controls are defined as described in the 
legend to Figure 3.3. Representative histograms are shown for each cytokine. 
Next, using multiplex cytokine detection methods to measure overall quantities of 
cytokines released into cell culture supernatant by T cells upon activation on their 
respective targets, we observed no defects in cytokine production by CTLs activated by 
traversed, as compared to nontraversed HC-04. In fact, there was an increase in 
production of IFNγ, IL-13, IL-2, IL-4, IL-8 and TNFα by CTLs activated on traversed 










cells (Table 3.1). Interestingly, exposure to nontraversed cells also resulted in more 
efficient release of the same cytokines by CTLs, as compared to stimulation with 
noninfected hepatocytes. 
 
Table 3-1. Cytokines (ng/mL) released by CTLs activated on HC-04 cells 30 h pi 
 
  
Stimulator GLC pep IFNγ IL-10 
IL-12 
p70 IL-13 IL-1β IL-2 IL-4 IL-6 IL-8 TNFα 
Noninfected - 48.8 0.1  0.2 17.2 0.0 34.8  0.2 0.2 12.3 0.2 
Noninfected 10 
-8 M 101.1 0.3 0.0 32.5 0.1 42.3 0.6 0.4 50.6 3.2 
Noninfected 10 -7 M 1140.5 0.4 0.6 244.4 0.1 223.8 27.8 0.7 199.7 103.9 
Nontraversed - 55.1 0.1  0.2 17.7 0.1 32.5 0.1 0.3 12.2 0.5 
Nontraversed 10 
-8 M 95.1 0.1 0.3 31.3 0.1 36.1 0.5 0.5 32.4 2.9 
Nontraversed 10 -7 M 2590.9 0.9 0.6 416.6 0.1 462.6 51.0 0.6 224.9 235.9 
Pf traversed - 50.8 0.1  0.2 16.2 0.2 31.1 0.2 0.2 17.1 0.5 
Pf traversed 10 
-8 M 140.3 0.4 0.5 52.6 0.1 49.9 1.6 0.6 100.2 6.1 
Pf traversed 10 -7 M 4867.8 1.1 0.9 473.8 0.2 771.7 83.9 0.8 355.2 451.2 
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Traversed hepatocytes induce activation markers on the surface of responding 
CTLs 
In parallel with cytokine release, activated CD8+ T cells alter expression of a 
number of cell surface antigens involved in signaling events. Upregulation of CD69, a 
signaling membrane glycoprotein involved in induction of T cell proliferation, CD25, the 
IL-2R α subunit, and programmed death ligand 1 (PD-L1) were induced on resting CD8+ 
effector T cells to a comparable extent after incubation with noninfected, nontraversed or 






Figure 3-5. Cell surface activation markers expressed by CTLs specifically triggered by traversed or 
nontraversed hepatocytes. 
Cell sorting was done 4 h pi and peptide-pulsed hepatocytes were used as stimulators for 
GLC peptide-specific CTL clone LF8 at 6 h pi. Expression of CD25, CD69 and PD-L1 
was assessed by immunostaining followed by flow cytometry at 24 h (A) and 48 h (B) 
post incubation. Unstimulated T cells were used to define steady levels of CD25, CD69 
and PD-L1 expression. Data from one representative of three experiments performed for 
each marker. Shaded histograms - isotype control antibodies, numbers indicate MFI of 
marker-specific antibody staining.  
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CD8+ T cells efficiently degranulate in response to stimulation by hepatocytes 
traversed with P. falciparum 
Degranulation is believed to be the major effector function of CD8+ T cells 
resulting in perforin-granzyme mediated cell death of the target (reviewed in (Ewen et al. 
2012)). CD107, a component of the lysosome membrane, is often used as a marker of 
cytotoxic granule release by NK and T cells (Betts et al. 2003). Six to eight percent of T 
cells had low surface expression of CD107 prior to specific stimulation, whereas in CTL 
cultures incubated with noninfected, nontraversed or traversed hepatocytes pre-pulsed 
with the relevant CTL peptide epitope, the number of CD107-positive cells increased by 
several fold, indicating efficient degranulation (Figure 3.6). All three hepatocyte 




Figure 3-6. Degranulation of CTLs induced by traversed and nontraversed hepatocytes. 
Expression of CD107 degranulation marker was measured in CTLs incubated with 
traversed, nontraversed or noninfected HC-04 cells pre-pulsed with GLC peptide as 
described in Materials and Methods. Cells without peptide served as control stimulators. 
(A) Representative histogram plots are shown. Shaded histograms (isotype controls) 
demonstrate gating strategy. Numbers reflect percentages of cells with high CD107-
specific fluorescence. (B) Summary of data obtained from three independent cultures. (C) 
CD107-MFI for one representative of two independent experiments is shown. ns, non 






























































Hepatocytes traversed by P. falciparum sporozoites trigger specific proliferation 
of CD8+ CTLs 
Amplification of the antigen-specific T cell pool is a desirable outcome of specific 
T cell receptor (TCR) triggering. CTL proliferation was measured as a decrease in 
fluorescence of CFSE-labeled T cells following stimulation with noninfected, 
nontraversed or traversed hepatocytes pre-pulsed with the relevant peptide at two 
different concentrations (Figure 3.7A). T cell proliferation, measured as percentages of 
CFSElow CD8+ T cells co-incubated with the three different hepatocyte populations, was 
dependent on the specific peptide concentration and was not affected by hepatocyte 
traversal (Figure 3.7B). Accordingly, no significant differences were observed in the 
mean fluorescent intensities of CFSE that reflect the average number of divisions of each 
T cell (Figure 3.7C). Thus, traversal does not affect the ability of hepatocytes to trigger 
specific proliferation of CD8+ CTLs. 
Altogether, these data show that traversed hepatocytes have no intrinsic 
alterations in the capacity to stimulate CTL effector functions as compared to 
nontraversed or noninfected cells. When providing specific exogenous HLA-A*02-
restricted peptide on the surface of target hepatocytes, all three populations of HC-04 
cells stimulated secretion of pro-inflammatory cytokines, upregulated expression of 




Figure 3-7. Proliferation of CTLs triggered by traversed and nontraversed hepatocytes. 
Proliferative capacity of LF8 CTLs in response to noninfected, nontraversed or traversed 
hepatocytes pre-pulsed with the GLC peptide at the indicated concentrations was 
measured as CFSE dilution at day 5 post triggering. CFSE fluorescence intensity of 
nonstimulated cells was used as a control to establish a threshold for “CFSElow” cell 
population arbitrary defined below 10%. (A) Representative histograms are shown for 
each stimulator. Numbers are percentages of “CFSE low” cells. (B) Summary of data 
obtained from three independent cultures analyzed for each stimulator. Percentages of 
CFSElow T cells and mean fluorescence intensities of CFSE are shown for each 
stimulation condition. ns, not significant comparing groups under line by ANOVA. 
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3.3.4 Soluble factors released either by traversed hepatocytes or by T 
cells activated on traversed hepatocytes do not impose in-trans effects 
on T-cell activation  
Cytoplasmic contents of traversed cells are released into culture medium during 
sporozoite traversal in vitro (Coppi et al. 2007). Therefore, it is conceivable that cellular 
contents released, as well as soluble factors produced by activated CTLs at the site of 
immune activation, may affect nearby cells, including both target hepatocytes and 
effector T cells. To address possible trans effects of traversal on neighboring cells, we 
activated CTLs with specific peptides in the presence of cell culture supernatants 
collected from sorted traversed and nontraversed HC-04 cells every 12 hours during the 
first 4 days pi. No differences in the efficacy of T cell activation were observed under 
these conditions (Figure 3.8), indicating that traversal of hepatocytes is unlikely to 
influence local T cell activation in trans.  
To determine whether T cell activation by traversed cells can influence cell 
surface phenotype in a bystander manner through production of soluble factors, we 
monitored surface expression of PDL-1 and HLA-A*02 on hepatocytes, both of which 
are known to be upregulated in response to pro-inflammatory cytokines. We found that 
hepatocytes exposed to soluble factors released by CTLs upon activation by noninfected, 
nontraversed, or traversed cells had comparable upregulation of PDL-1 and HLA-A*02 
(Figure 3.8B), demonstrating similar in trans effects mediated by T cells activated on 




Figure 3-8. Traversal of hepatocytes does not mediate in-trans effects modulating T cell activation. 
(A) Intracellular IFNγ detection in CTLs activated in the presence of supernatants 
obtained from traversed or nontraversed hepatocyte cultures and collected at different 
time points (6-96h) post infection. Each bar is a summary of data obtained from three 
independent CTL cultures. (B) HLA-A*02 and PD-L1 expression on HC-04 cells 
incubated with soluble factors released by CTLs activated on traversed and nontraversed 
cells. GLC-specific CTLs were activated on targets 24 h pi and culture supernatants 
collected 16 h post-activation were applied onto HC-04 cells for another 24 h. Expression 
of HLA-A*02 and PD-L1 was assessed by immunostaining followed by flow cytometry. 
Shaded histograms define isotype control staining intensity and outline gating strategy. 
Numbers indicate MFI of marker-specific staining observed in control and SN-treated 
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3.3.5 Traversed cells support endogenous processing and presentation of 
retained CSP and activate parasite-specific CD8+ T cells 
After establishing the ability of traversed hepatocytes to serve as non-professional 
APCs, we next determined if parasite-specific antigens could be presented by traversed 
hepatocytes. The possibility of presentation of parasite antigens from invaded and 
traversed hepatocytes remains an important question in the understanding of CTL 
responses to liver stage malaria infection (Bongfen et al. 2007). Using human CTL clone 
specific for HLA-A*02- restricted epitope PfCSP327-335 (YLNKIQNSL)(Bonelo et al. 
2000), we assessed the ability of Pf -traversed HC-04 cells to stimulate IFNγ from CTLs. 
Staining of this CTL clone with a specific tetramer followed by flow cytometry revealed 
that the entire population expressed the TCR (Figure 3.8A) and secreted IFNγ following 
specific peptide stimulation (Figure 3.8B). About 2-3% of the clonal CSP-specific 
lymphocytes secreted IFNγ when stimulated with either sorted traversed or bulk infected 
hepatocyte cultures at 1:1 traversed hepatocyte-to-CTL ratio at different time points pi 
(Figure 3.8C, D). Given the clonal nature of the responder T cells, the low frequency of 
activated CTLs probably reflects the percentage of traversed cells capable of presenting 
this C-terminal CSP epitope on MHC class I and correlates with the frequencies of 
traversed cells harboring cytoplasmic or/and nuclear CSP (Chapter 2). Pre-treatment of 
sporozoites with cytochalasin D (shown to inhibit traversal, Figure 2.1) prior to infection 
decreased the percentage of specific CTLs secreting IFNγ nearly to the levels obtained 
with stimulation by non-infected cells (Figure 3.8D). To our knowledge, these data are 
the first direct demonstration of endogenous MHC class I-restricted antigen presentation 
of P. falciparum CSP by traversed cells. 
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3.3.6 CD8+ T cells limit liver stage infection in vitro 
It has been previously described that two major cytokines released upon T cell 
activation, IFNγ and TNFα, can limit development of malaria parasites in the liver 
(Ferreira et al. 1986; Schofield et al. 1987). To determine the consequences of CSP-
specific CTL activation, we assessed the ability of these T cells to limit the development 
of P. falciparum EEFs, a goal of immune responses generated in response to a liver stage 
vaccine. Co-incubation of YLNK-specific T cells with HC-04 cell cultures infected with 
P. falciparum 3D7-GFP parasites reduced the number of GFP+ hepatocytes by 60% and 
39%, when added at 24 h and 48 h pi, respectively (Figure 3.8E). No reduction in the 
number of infected cells was seen in HC-04 cultures incubated with irrelevant EBV-
specific HLA-A*02-restricted human CTLs. Due to technical limitations of experimental 
systems currently available for P. falciparum liver stages, we were unable to discriminate 
between the possible bystander effect of cytokines released by CSP-specific CTLs 
activated on traversed cells and the direct recognition and elimination of infected 
hepatocytes. However, several lines of evidence indirectly support a role for traversed 
cells in the control of EEF development via activation of CSP-specific CTLs. First, there 
are about 150 times more traversed cells present in infected cultures than EEFs, (see 
Figure 2.1), making them more likely to engage CSP-specific CTLs that are in close 
proximity to invaded cells. Second, CSP-specific CTL activation by sorted, traversed 
cells leads to production of IFNγ (Figure 3.8C), known to limit development of EEFs. 
Third, CSP can be detected in P. falciparum infected cells up to 4-5 days pi (Sacci et al. 
2006) and, therefore, if endogenously processed and presented, should serve as a 
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rejection antigen within this time frame. However, our data indicate, that more efficient 
control of EEFs requires early, (by 24 h pi), exposure of infected cultures to CSP-specific 
CTLs, which are likely to recognize CSP present in and processed by traversed cells. 
Generation of a novel strain of P. falciparum parasites deficient in traversal may shed 





Figure 3-9. Traversed hepatocytes can activate CSP-specific CTLs. 
CSP-specific CTLs recognize HLA-A*02+ HC-04 traversed with P. falciparum 
sporozoites. (A) Specificity of CD8+ HLA-A*02-restricted CSP-specific CTL clone was 
confirmed by binding to specific HLA-A*02 tetramer containing YLNKIQNSL peptide 
and IFNγ secretion assay following activation with the peptide pulsed targets (B). 
Numbers indicate percentages of cytokine secreting CTLs. IFNγ capture assay is 
described in Materials and Methods. (C) Representative dot plots indicate IFNγ release 
from CSP-specific CTLs stimulated with HC-04 cells, either uninfected or separated into 
traversed and nontraversed populations 24 h pi or (D) Pf-infected HC-04 cells were used 
as stimulators 48 and 72 h pi with sporozoites pre-incubated or not with cytochalasin D. 
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(E) CSP-specific CTLs can limit Pf infection in HC-04 cells. CSP-specific (YLNK) or 
control EBV-specific (GLC) CTLs were incubated with Pf infected HC-04 beginning at 
24 or 48 h pi. Percentage of infected (GFP+) hepatocytes of viable (PI-) was determined 
at 72 h by flow cytometry.  
3.4 Discussion 
The well-established role for CD8+ T cells in the control of malaria liver stage 
infection suggests that liver resident cells possess Plasmodium antigen(s) and can serve 
as antigen presenting cells to trigger parasite-specific CTL responses. Currently, two 
subsets of hepatocytes are known to contain malarial antigens: sporozoite-traversed, and 
invaded hepatocytes that harbor developing EEFs. Though a number of studies suggested 
that infected cells can activate parasite-specific CTLs (Bongfen et al. 2007; Trimnell et al. 
2009; Cockburn et al. 2013), only one has attempted to address this issue in regard to 
traversed cells (Bongfen et al. 2007). 
In studies presented here, traversed cells were identified by dextran uptake. While 
we do not formally exclude the presence of invaded cells, whether harboring aborted or 
developing parasites, within populations of dextran-positive or dextran-negative cells, our 
data support a minimal role of invaded cells in T cell activation in this in vitro P. 
falciparum infection system. P. falciparum invaded cells are exceedingly rare as 
compared to traversed cells (Ch. 2), making traversed but uninvaded cells more likely to 
be found proximally to CTLs, and to be the source of stimulation. Therefore, to our 
knowledge, we present the first direct demonstration of the ability of human hepatocytes 
traversed with P. falciparum sporozoites to trigger an apparently complete program of T 
cell activation in an MHC class I-restricted, antigen-specific manner. Antigen presenting 
capacity of traversed cells was found to be equivalent to nontraversed and noninfected 
hepatocytes, as determined by similar surface expression of HLA-ABC (Figure 3.1). 
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Additionally, noninfected HC-04 cells transiently transfected to express CSP had steady-
state expression of HLA-ABC and responded to pro-inflammatory cytokines to the same 
degree as control vector-transfected cells (Figure 3.2). Together, neither sporozoite 
traversal nor the presence of ectopic CSP caused obvious alterations in the 
immunogenicity of human hepatocytes, that contradicts a previous report (Singh et al. 
2007). 
CTL activation by traversed cells, manifested as release of cytokines (Figures 3.3, 
3.4), upregulation of surface activation markers (Figure 3.5), degranulation (Figure 3.6) 
and proliferation (Figure 3.7) equivalent to that induced by stimulation with nontraversed 
or noninfected hepatocytes. These effects were not specific to T cell or target cell, as we 
utilized two different T cell clones and two targets: HC-04 cell line and primary human 
hepatocytes (Figure 3.4, data not shown). Interestingly, though similar numbers of T cells 
produced cytokines when stimulated by noninfected, traversed or nontraversed 
hepatocytes (Figure 3.4), higher amounts of IFNγ, TNFα, IL-2, -4, -8, and -13 were 
detected in co-culture supernatants when traversed cells were used a stimulators (Table 
3.1). This was not due to enhanced production of these cytokines triggered by traversed 
hepatocytes non-specifically in antigen-independent manner (Table 3.1, no peptide), but 
could reflect enhanced adhesion of T cells to traversed hepatocytes due to increased 
expression of ICAM-1 on traversed cells (Figure 3.1).  
We have shown that the proteasome is involved in the turnover of at least some 
CSP moieties retained by traversed hepatocytes (Chapter 2). Thus, equipped with surface 
HLA class I complexes and adhesion molecules (Figure 3.1), traversed cells have the 
potential to present parasite antigens and activate parasite-specific CD8+ T cells. We 
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showed that traversed HLA-A*02 HC-04 hepatocytes could indeed activate CD8+ T cells 
specific for an HLA-A*02-restricted C-terminal epitope of P. falciparum CSP (Figure 
3.8). We hypothesize that other antigens, if shed into traversed cells during traversal, may 
activate parasite-specific CTLs in a similar fashion. If such activation by traversed cells 
occurs in vivo, we suggest several possible effects on liver stage infection.  
Local production of cytokines released by activated CTLs, such as IFNγ and 
TNFα, which are known to limit EEF development (Mellouk et al. 1991; Depinay et al. 
2011), may either directly inhibit the expansion of parasites within infected cells by 
inducing nitric oxide production (Sedegah et al. 1994; Klotz et al. 1995), or increase the 
immunogenicity of infected cells via increased expression of surface MHC class I 
complexes. We have previously shown that P. berghei infected HC-04 cells upregulated 
expression of genes involved in the MHC class I presentation pathway in response to 
treatment with activated supernatant through early time points post infection (Ma et al. 
2013).  Thus, traversed cells presenting antigen to Plasmodium-specific CTLs may 
improve the host control of infection. 
Alternatively, traversed cells may serve as an immune decoy for parasite-specific 
CTLs, engaging CD8+ T cells in prolonged interactions provided by elevated ICAM-1 
expression on the cell surface and deviating effectors from direct interaction with MHC 
class I expressing infected hepatocytes (Ma et al. 2013). However, we were not able to 
compare ICAM-1 expression on infected cells to that on traversed cells in these studies, 
as hepatocyte invasion occurs only rarely in HC-04 cells (Chapter 2).  
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These scenarios could be experimentally addressed in the future using genetically 
modified P. falciparum parasites incapable of traversal but competent to invade 
hepatocytes, such as SPECT -disrupted strains (Ishino et al. 2004).  
Until now, traversal by Plasmodium sporozoites in the liver parenchyma has been 
mainly viewed as a prerequisite for efficient infection of hepatocytes preceded by the 
exocytosis of sporozoite apical organelles (Mota et al. 2002). In light of our findings that 
traversed cells maintain the ability to stimulate a full array of CD8+ T cell activation and 
that at least one liver stage antigen, CSP, is retained, processed, and presented, we 
propose a novel view on the traversed cells as a potential site of parasite specific immune 
activation. This presents additional questions of whether parasite-specific CTL activation 
by traversed cells benefit the host in controlling infection, or the parasite, in misdirecting 
important effector responses.   
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Chapter 4. DETECTION OF NATURALLY INDUCED CSP-
SPECIFIC T CELL RESPONSES 
4.1 Introduction 
In malaria-endemic regions, populations are repeatedly exposed to and re-infected 
with Plasmodium without the developing sterile protection. Protection from clinical 
symptoms, but not from parasitemia, develops with age and repeated exposure, a 
signature of naturally acquired immunity, reviewed in (Langhorne et al. 2008; Doolan et 
al. 2009).   
Both humoral and cellular immune responses to Plasmodial antigens are often 
detected following natural infection, but provide incomplete protection. This may be due 
to many factors, including insufficient effector functions or failure to generate long-term 
memory responses, especially considering the context of other co-morbidities such as co-
infections and often observed malnutrition that affect developing regions afflicted by 
malaria.  
Antibody responses against a broader panel of Plasmodium antigens develop with 
age and repeated exposure. These antibody profiles tend to be associated with protection 
from severe malaria, but do not prevent the onset of parasitemia (Barry et al. 2011; 
Greenhouse et al. 2011; Hoffman et al. 1987). Similar dynamics in antibody responses 
are also observed following periods of high malaria transmission in regions with seasonal 
transmission patterns, and in some cases, higher antibody levels that persist through low 
transmission season are predictive of less severe malaria during the next season 
(Crompton et al. 2010). However, the neutralizing capacity of these antibodies is poorly 
understood.  
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Studies have identified epitope-specificities and effector functions of malaria-
specific T cells in naturally exposed populations. Relevant to vaccine development, 
MHC-class I-restricted T cell epitopes to liver stage antigens such as CSP, LSA-1, TRAP, 
EXP-1, and STARP (Anum et al. 2015; Offeddu et al. 2012; Lyke et al. 2005) were 
detected in individuals from malaria endemic regions, and there are efforts to increase the 
scale of these studies for antigen discovery using high throughput approaches (Grubaugh 
et al. 2013).  
CSP-specific CD8+ T cells are often detected in peripheral blood of donors from 
endemic areas, albeit with low frequency (reviewed in Doolan et al. 2009). Several CD8+ 
T cells to specific to HLA-A*02-restricted peptides from the N- and C-termini have been 
detected in naturally exposed individuals, some of which may promiscuously bind to 
other HLA alleles (Blum-Tirouvanziam et al. 1995; Doolan et al. 1997; Wang et al. 1998; 
Lyke et al. 2005). Novel CTL epitopes from CSP not previously detected in the field 
were characterized following administration of an Adenovirus-vectored CSP-based 
vaccine (Sedegah et al. 2013), which may offer insight into epitopes that could be 
protective in vaccination that are not induced in natural exposure.  
Though it is clear that naturally exposed individuals do mount humoral and 
cellular responses, vaccines tested in endemic populations are less effective than in naïve 
individuals (Guilbride et al. 2010; Cohen et al. 2010), for two possible reasons: genetic 
diversity in parasites that precludes efficient control of multiple circulating parasite 
strains, or less effective immune responses induced and maintained in the context of 
chronic antigenic stimulation by malarial antigens and other co-infections. Epidemiologic 
studies revealed alterations in the quality of adaptive immune responses in multiple 
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regions in different transmission settings (Butler et al. 2011; Illingworth et al. 2013; 
Portugal et al. 2014). Chronically exposed Malian children had features of an  
immunoregulatory T cell response that limited inflammation while maintaining low 
levels of infection (Portugal et al. 2014). B- and T-cell exhaustion have been investigated 
in repeated malaria exposure, manifesting as an expansion of atypical memory B cells 
and CD4+ T cells expressing PD-1 and LAG-3 (Illingworth et al. 2013). Increased 
expression of PD-1 on CD4+ T cells was detected in parasitemic Malian children, a 
phenomenon reproduced experimentally in mice. Furthermore, functional antibody-based 
blockade of PD-L1 and LAG-3 improved antibody and CD4+ T cell responses to blood 
stage antigens, resulting in better control of P. yoelii infection (Butler et al. 2011). 
In our studies, we aimed to characterize the frequencies and repertoire of the 
MHC-I-restricted, CD8+ T cell responses to CSP in naturally exposed individuals from a 
high-transmission region.  Using PBMCs and plasma from healthy adult donors living in 
Mali, we evaluated the presence of HLA-A*02-restricted CSP-specific T cell responses, 
measured CSP-specific IgG to each functional domain of CSP, and evaluated the effects 
of plasma from exposed individuals on in vitro infection of human hepatocytes with P. 
falciparum sporozoites. While we detected evidence of exposure (anti-MSP-1 and MSP-2 
IgGs) in 78% of healthy adults and anti-CSP IgG in 62%, only 22% had detectible T cell 
responses to CSP as measured by IFNγ production in ELISpot assays. We found that 
Malian plasma samples significantly inhibited sporozoite motility as compared to plasma 
from non-exposed US donors. However, this inhibition neither correlated with measured 
anti-CSP IgG nor with inhibition of sporozoite invasion. We also found overall alteration 
in the composition of the T cell compartment, such as skewing of the CD4+:CD8+ T cell 
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ratio and increased expression of exhaustion marker PD-1. Altogether, we present a 
comprehensive characterization of CSP-specific humoral and cellular responses in 
populations from a malaria-endemic region, and the functional effects of plasma on liver 
stage infection. Our preliminary studies suggest a potential therapeutic benefit of PD-1 
blockade for enhancement of T cell function in this population. 
4.2 Materials and Methods 
Ethics statement 
We used human samples collected by collaborators in Mali, (Diakite Mahamadou, 
Malaria Research and Training Center, Bamako, Mali.) IRB approval, sample collection, 
processing and storage were done according to IRB protocol. De-identified samples were 
sent to JHU and processed as specimens with no identifiers. 
Study site and sample collection 
Limited amounts of peripheral blood lymphocytes and serum were collected from 
45 adult volunteers at a single study site in Dangassa, Mali in December, 2012 (“ML”) 
and June, 2013 (“AK”). Inclusion criteria were absence of clinical signs and symptoms of 
HIV or other acute infection and hemoglobin levels > 8.5 g/dL. Parasitemia was detected 
by blood smear in 4 of 20 AK donors. Samples were cryopreserved and shipped to Johns 
Hopkins Bloomberg School of Public Health for analysis.  Ten control serum samples 
(further referred to as “US”) from US donors with no records of previous exposure to 
malaria infection were provided by Dr. A. Durbin (Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD). “NHS” is commercially available AB Human Serum 
(Life Technologies, Grand Island, NY). Control “US” PBMC samples were obtained 
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from buffy-coats (New York Blood Center, New York, NY) and purified by density 
gradient centrifugation using Lymphocyte separation medium (Cellgro, Pittsburgh, PA, 
USA). For studies of EEF development, a smaller subset of plasma samples was 
randomly selected. 
Detection of immunoglobulins specific to P. falciparum antigens by Enzyme-
Linked Immunosorbent Assay (ELISA) 
Plasma samples were screened by ELISA for IgGs specific for P. falciparum 
blood stage antigens (MSP-1 and MSP-2) and CSP. MSP-1 (MSPF15-R) and MSP-2 
(MSP25-R) proteins were purchased from Alpha Diagnostic International (San Antonio, 
TX). Recombinant CSP (rCSP21-382) was purchased from Pfenex, Inc. (San Diego, CA). 
The N-terminal CSP signal peptide (aa 1-20) was synthesized by the Johns Hopkins 
School of Medicine Sequencing and Synthesis Facility (Baltimore, MD). The central 
repeat region (NANP)x7 and C-terminal peptides overlapping aa 311-397 of P. 
falciparum 3D7 CSP sequences were gifts from F. Zavala (Johns Hopkins Malaria 
Research Institute, Baltimore, MD).  
Flat-bottom MaxiSorp 96-well plates (ThermoFisher, Rochester, NY) were coated 
with 1 ng/µl of target antigen overnight at +4Cº in 0.05M carbonate-bicarbonate buffer 
(pH 9.6) and subsequently blocked with 1% bovine serum albumin in PBS. All plasma 
samples were screened at 1:100 dilutions in triplicates. Following incubation with 
secondary goat anti-human IgG-AP and PNPP solution (ThermoFisher) optical density 
(OD) was detected at 405 nm. Two thresholds of positivity were established for each 
individual antigen (as indicated in relevant parts of Results section): mean OD exceeding 
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the mean plus 2 or 3 standard deviations from the mean OD detected for each antigen in 
negative control samples (sera from US donors).  
In vitro infection of human hepatocytes with P. falciparum  
Human hepatocyte line HC-04 (Sattabongkot et al. 2006) was seeded to 
confluence in 48-well plates. P. falciparum 3D7HT-GFP (Talman et al. 2010) or P. 
berghei ANKA GFP (Franke-Fayard et al. 2004) sporozoites were isolated from salivary 
glands of Anopheles stephensi mosquitoes 17 or 22 days post-bloodfeed, respectively. 
Sporozoites were purified on OptiPrep density gradient (Sigma, St. Louis, MO) and 
infection procedures were done as previously described (Ma et al. 2013).  
To assess sporozoite motility, traversal experiments were performed as described 
previously (Prudêncio et al. 2008). Sporozoites were added at 1:1 ratio in IMDM 
containing 100 U/ml penicillin, 100 µg/mL streptomycin, 2mM L-glutamine (Gibco, 
Grand Island, NY) and 1% of indicated plasma from Malian donors, control normal 
human serum (Life Technologies, Grand Island, NY) or Fetal Bovine Serum (Corning 
Cellgro, Manassas, VA) in the presence of 0.2 µg/ml of 10,000 MW dextran-
tetramethylrhodamine (Molecular Probes, Grand Island, NY). For assessment of EEF 
development, experimental serum was either added with sporozoites simultaneously 
during invasion (0-48h) or 2 h later, after removal of uninvaded sporozoites (2-48h). To 
prevent bacterial and fungal contamination, infected hepatocyte cultures were extensively 
washed 2 and 24 h pi, when 5 µg/ml of Fungizone (Life Technologies) was added and 
experimental serum was also replenished. The percentage of cells infected with GFP-
transgenic parasites was assessed by flow cytometry at 48 h pi. Only bacteria-free 
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hepatocyte cultures were analyzed, as determined visually and by the lack of 
FSClowSSClow contaminants.  
IFNγ enzyme linked immunospot (ELISpot) assays 
All PBMC samples used in this study were frozen as live cell suspensions in the 
presence of 10% DMSO and stored in liquid nitrogen prior to analysis.  Thawed PBMCs 
were propagated in RPMI supplemented with 10% FCS for duration of each assay. Cell 
viability was assessed using trypan blue. MultiScreen IP Filter plates (Millipore, Billerica, 
MA) were pre-wetted briefly with 35% ethanol, washed with PBS, and coated with 1 
mg/ml of IFNγ-specific antibody (clone 1-D1K, MAbTech, Cincinnati, OH) overnight at 
4°C. To provide conditions for possible cross-presentation of CSP, rCSP21-382 (Pfenex) 
complemented by N- (aa1-20) and C- (aa 342-397) terminal CSP peptides (1 µg of total 
protein per well) were added directly to a portion of PBMC cultures 4 hours after thaw, 
whereas remaining PBMCs were left unstimulated. Twenty-four hours following thaw, 
ELISpot plates were washed with PBS and blocked with 10% FCS for 2 h. Aliquots 
containing 50,000 trypan blue-negative cells were added in duplicates for each 
stimulation condition. The following conditions were used to stimulate IFNγ production 
from PBMCs:  5 µM PHA (Sigma, St. Louis, MO), 5 µg/mL CEF peptide plus control 
(AnaSpec, Fremont, CA), a pool of 5 HLA-A*02-restricted viral peptides (5µM final 
concentration containing equal amounts of each peptide) including Influenza-derived 
peptides GILGFVFTL (Matrix58-68) and FMYSDFGFI (PA46-54), EBV-derived peptides 
CLGGLLTMV (LMP2A426-434) and GLCTLVAML (BMLF1280-288), HCMV-derived 
NLVPMVATV (pp65495-503), a pool of 6 HLA-A*02-restricted CSP peptides, 
(MMRKLAILSV1-10, AILSVSSFL6-14, HIKEYLNKI315-323, YLNKIQNSL319-327, 
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GLIMVLSFLF386-395, IMVLSFLFL388-397)(5µM final concentration), or DMSO as a 
vehicle control. PBMCs from cultures stimulated with rCSP (Pfenex) complemented by 
N- (aa1-20) and C- (aa 342-397) terminal CSP peptides 24 h prior to assay were also 
plated into ELISpot plates at the same cell density.  Following 20 h incubation at 37ºC 
and cell removal, membranes were probed with IFNγ-biotin (MAbTech), anti-biotin-AP 
(Vector, Burlingame, CA), and developed with BCIP/NBPT (Pierce, Rockford, IL). Spots 
were counted with Immunospot 5.0 (CTL, Shaker Heights, OH). Positivity for each 
sample was determined as number of spots exceeding the mean plus 2 standard 
deviations of values detected in negative control wells stimulated with DMSO. 
Flow-cytometry assays for detection of surface antigens 
Twenty four hours post thawing of PBMCs, antibodies specific to the following 
antigens were used to determine the presence of surface markers on PBMCs: CD3, CD4, 
CD8, (BioLegend, San Diego, CA, or BD Biosciences, San Jose, CA), HLA-A*02, clone 
BB7.2 (BD Biosciences) and PD-1 (BioLegend, San Diego, CA). Relevant isotype and 
fluorochrome control antibodies were used to determine background fluorescence in each 
experiment. Data were acquired with CellQuest Pro Software on FACSCaliburTM (BD) 
and analyzed in FlowJo (TreeStar, Ashland, OR).  
Effect of allogeneic plasma on T cell subset composition and PD-1 expression 
PBMCs from “negative control” US donors were incubated for 5 days with 
plasma samples from US and Malian subjects, at a concentration of 10 v/v% in RPMI 
containing 100 U/ml penicillin, 100 µg/mL streptomycin, 2mM L-glutamine, or in serum-
free AIM-V medium (Gibco). Surface markers and PD-1 expression were assessed by 
flow cytometry as described above.  
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PD-1 blockade and IFNγ secretion assays 
PBMCs pre-incubated with 10µg/ml of PD-1 blocking antibody or IgG1 isotype 
control antibody (BioLegend) were transferred into 96-well plates pre-coated with 
10µg/well of anti-CD3 and anti-CD28 antibodies (BD Biosciences). For IFNγ secretion 
assays, following 3h incubation at 37ºC IFNγ capture was performed following 
manufacturer’s protocols (Miltenyi Biotec, Auburn, CA). Percentage of CD4+ and CD8+ 
T cells secreting IFNγ was determined by flow cytometry. Alternatively, ELISpot assays 
were performed as described above. 
Statistical Analysis 
Statistical analyses were performed in Prism 6.0 (GraphPad Software, Inc., La 
Jolla, CA) as indicated in Figure Legends.  
4.3 Results 
The current study included plasma and peripheral blood from 45 healthy adults in 
Dangassa, Mali on the Niger River, south of Bamako, an area of high P. falciparum 
transmission (World Health Organization 2014). Previously, sample collection was 
conducted in December 2012 (“AK”), post-rainy season, and June 2013 (“ML”), prior to 
the next rainy season (Table 4.1). Ages ranged from 18 to 56, mean 37 (AK group), and 
25 to 64, mean 43 (ML group). Four AK subjects were parasitemic at the time of 
collection. US control serum and PBMC samples included in the study were obtained 
from different donors.  
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Table 4-1. Characteristics of blood donors. 
 










Jan-12 E 32 M
F 20 M
G 27 F
Sep-12 H 18 F
I 22 F
J 19 M
n=10 mean = 27 60% M (6)
40% F (4)
AK
Dec-12 46 18 F 10.4 150Tf
47 40 F 10.8 0
48 38 M 10 0
49 21 M 15.5 0
50 54 M 15 0
51 48 M 14 0
52 46 M 14 0
53 38 M 17.2 0
54 26 F 14.9 0
55 37 M 15.7 0
56 50 F 13.8 0
57 28 F 10.7 0
58 31 M 15.1 0
59 36 M 15.7 75Gf
60 38 M 15.6 300Tf
61 56 F 15.2 0
62 24 F 14.4 0
63 35 F 11.6 0
64 45 F 10.4 1050Tf
65 38 F 13.7 0
n = 20 mean = 37 50% M (10)
50% F (10)
ML
Jun-13 1 51 M 14.6 0
2 57 M 11.8 0
3 64 M 10.2 0
4 45 M 15.5 0
5 51 M 13.9 0
6 27 F 14.4 0
7 58 F 15.7 0
8 40 F 14 0
9 32 F 13.8 0
10 28 F 14.6 0
11 40 F 10.8 0
12 40 F 14.4 0
13 57 M 15.6 0
14 45 M 15.2 0
15 50 F 13.8 0
16 50 F 11.6 0
17 49 F 15.2 0
18 51 F 14.4 0
19 30 F 15.8 0
20 46 M 13.7 0
21 45 M 10.8 0
22 30 F 14.9 0
23 25 F 10 0
24 29 F 15 0
25 27 F 14.8 0




4.3.1 Plasma antibodies to MSP-1 and MSP-2, CSP 
As antibody responses to Plasmodium antigens are often detected in malaria-
endemic regions, we screened plasma from healthy adult donors for IgG specific for 
blood stage antigens MSP-1 and MSP-2, and sporozoite/liver-stage antigen CSP. Blood 
stage antigens were included for evidence of infection, and antibodies against CSP were 
analyzed to ensure that this antigen of interest as a target of cellular immunity had been 
cross-presented, suggesting the possibility for T cell responses. Antibody responses to 
CSP were mapped to the following antigenic peptides: 1) commercially available Pfenex 
rCSP (aa 21-382), the full length protein excluding the N-terminal signal sequence and 
presumed C-terminal GPI anchor. Pfenex includes all functional domains of CSP, only 
omitting small portions from the utmost N- and C-termini. 2) the central repeat region 
represented by (NANP)x7, 3) the N-terminal signal sequence excluded from Pfenex (aa 
1-20), and 4) two overlapping peptides that span the C-terminus, including the GPI 
anchor excluded from Pfenex (Fig 4.1A).  The central repeat region contains many copies 
of an immunodominant B cell epitope (Zavala et al. 1983; Dame et al. 1984), while the 
C-termini includes multiple CD4+ and CD8+ epitopes (Doolan et al. 1997; González et al. 
2000; Blum-Tirouvanziam et al. 1995). Thus, we sought evidence that regions of CSP 
containing T cell epitopes had been cross-presented to generate B cell responses. 
ELISA assays were first performed to experimentally assess evidence of immune 
responses to previous P. falciparum infection. Plasma were screened for IgG specific for 
a combination of abundantly expressed blood stage antigens MSP-1 and MSP-2, as 
robust levels of anti-MSP119 IgG are induced following even a single exposure to malaria 
in low-transmission regions (Clark et al. 2012). Two positivity thresholds of OD 
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exceeding the mean plus 2 or 3 standard deviations of sera from ten healthy US donors 
were established, herein referred to as “2 SD” and “3 SD” thresholds. Specific OD values 
in thirty-two of 45 (71%) of Malian subjects exceeded the conservative 3 SD threshold, 
and in 35/45 (78%) of donors exceeded the more liberal 2 SD cutoff (Fig 4.1B). There 
was a trend toward greater percent of anti-MSP-1 and -2 positive donors in the AK group. 
While it was expected that nearly all subjects had experienced malaria throughout their 
lifetime, evidence of antibody responses exceeding our thresholds was observed in 78%.  
We detected IgGs recognizing the near full-length Pfenex rCSP at the 3 SD 
threshold in 21/45 (47%) donors (Fig 4.1B). As expected, almost all of these subjects 
(19/21) had detectable anti-MSP-1 and MSP-2 IgGs (Fig 4.1B). Overall recognition of 
the central repeat region, represented by (NANP)x7, was detected in plasma from 22/45 
donors using the conservative 3 SD threshold. All of these samples were also positive for 
Pfenex rCSP-specific IgG at least exceeding the 2 SD threshold. Fewer plasma samples 
had detectable IgG specific for the peptides including the termini, C311-397 (9/45, 20%) 
and N1-20 (3/45, 6.7%).  
Both the mean OD and the percentage of donors with antibodies to all sequences 
of CSP were slightly higher in the AK than ML group, though these differences were not 
statistically significant from each other, except for the percentage recognizing the long C-
terminal peptide (Fig 4.1C, D).  
Most studies of antibody responses to CSP rely exclusively on screening of the 
central repeat region (Clement et al. 2012), which comprises 42% of the total amino acid 
residues. Our expanded assessment confirmed that most anti-CSP IgG are directed 
towards the tandem repeats, but in some cases, detectable responses are also mounted 
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against the termini.  The functions of antibodies against each region are an important 




Figure 4-1. Mapping of CSP-specific IgG responses in plasma from Malian donors 
(A) Schematic of P. falciparum CSP functional domains with amino acid residues 
indicated. NT, N-terminus (red); CT, C-terminus (green), repeat region is shown in blue. 
Four polypeptides representing indicated CSP domains were used as capture antigens for 
ELISA: Pfenex rCSP21-382 (shown in purple) N1-20 (red), central repeat region (NANP)x7 
(blue), and  CT311-397 (green). (B) IgG reactivity to blood stage antigens MSP-1 and MSP-
2 or indicated regions of CSP in donor plasma from ML and AK Malian cohorts were 
detected by ELISA in triplicates. Solid boxes indicate that the mean OD value exceeded 
mean + 3 SD of values obtained with control US donors. Boxes with dotted pattern 
signify OD values greater than mean + 2 SD but less than mean + 3 SD of values 
detected in control US donors. Below table, numbers (top row) and percents (bottom 
row) relate to samples from each cohort with OD values exceeding mean + 3 SD 
threshold. (C) Bar graph shows total percentage of samples from ML (red) and AK 
(green) cohorts identified as positive when tested against indicated portions of CSP. Chi-
square test identified * p ≤ 0.05 comparing number of positive samples between AK and 
ML groups (D) IgG reactivity against MSP-1, MSP-2 and 4 different CSP regions were 
compared in plasma of Malian and US control donors. All samples were processed 
simultaneously for each antigen; OD values reflecting IgG reactivity detected in each 
sample are shown. Horizontal lines indicate mean values of each group. One-way 
ANOVA followed by Tukey multiple comparison testing identified * p ≤ 0.05, ** p ≤.01, 
*** p ≤.001 and **** p≤ .0001.  
4.3.2 Plasma from Mali donors inhibits sporozoite motility 
As high levels of CSP-specific antibodies have been shown to impair sporozoite 
motility and invasion (Mishra et al. 2012; Doolan & Martinez-Alier 2006), we 
investigated the ability of sporozoites to traverse HC-04 hepatocytes in the presence of 
plasma from malaria-exposed subjects. Interestingly, the presence of plasma from US 
control donors inhibited fluorescent dextran uptake by a mean of 24% over infection in 
the presence of FCS (Figure 4.2A). This “non-specific” inhibition of sporozoites by 
control US plasma, however, was significantly lower than the effect of Malian plasma, 
from both ML (62%) and AK (73%) groups (Figure 4.2A). This observation warrants 
further investigation to identify the possible “non-antibody” components circulating in 
human blood that can specifically impair the migration of P. falciparum, but not P. 
berghei sporozoites through human hepatocytes (Figure 4.2B).  
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While specific for P. falciparum, the inhibition of sporozoite motility was 
independent of the presence or the magnitude of Pfenex rCSP-specific IgG (Figure 4.2C, 
D). Plasma from Malian donors, regardless of the levels of anti-CSP antibodies in 
peripheral blood, strongly limited sporozoite traversal as compared to US plasma. 
Furthermore, there was no statistical correlation observed between OD values for 
antibodies recognizing each CSP peptide and inhibition of traversal in the US or ML 
groups (Figure 4.2D). Surprisingly, plasma from AK subjects had a statistically 
significant, though weak, negative correlation between the inhibition of traversal and 




Figure 4-2. Effect of plasma from Malian donors on sporozoite motility in vitro 






















































































































































































Group r p-value 
US -0.424 0.222 
ML -0.387! 0.068! 
AK -0.653 0.002 
Group r p-value 
US -0.423 0.222 
ML -0.295! 0.172! 
AK -0.586 0.007 
Group r p-value 
US 0.0455 0.901 
ML 0.209! 0.338! 
AK -0.656 0.002 
Group r p-value 
US -0.0344 0.331 
ML -0.0672! 0.761! 





Motility of P. falciparum sporozoites was assessed by in vitro traversal assays as 
described in Materials and Methods. (A) Comparison of traversal inhibition by plasma 
from ML and AK Malian cohorts and US control plasma samples. Traversal assays are 
described in Materials and Methods. Inhibition of traversal was calculated as percentage 
of traversed hepatocytes detected in the presence of Malian or US control plasma relative 
to that detected in the presence of FCS. (B) Comparison between the ability of randomly 
selected Malian plasma samples to inhibit P. falciparum and P. berghei sporozoite 
motility, measured in traversal assays. (C) Comparison of traversal inhibition by plasma 
from either US control or Malian donors (ML and AK cohorts combined) separated into 
samples with IgG reactivity to Pfenex21-382 either above (+) or below (-) 3 SD threshold. 
Horizontal lines (A,C) indicate mean values of each group. One-way ANOVA followed 
by Tukey multiple comparison testing identified * p ≤ 0.05, ** p ≤.01, *** p ≤.001 and 
**** p≤ .0001.  (D) Correlation between the IgG reactivity against indicated antigenic 
regions of CSP detected in plasma of Malian or US control donors and inhibition of 
traversal. Y-axes represent the decrease in percentages of traversed hepatocytes detected 
in the presence of plasma from US control or Malian donors, as compared to percentage 
of traversed hepatocytes observed in the presence of FCS, arbitrarily taken as 100%. X-
axes indicate OD values for individual plasma samples obtained from ELISA screening 
experiments (as described in Figure 4.1). Individual plasma samples are denoted by blue 
circles (US controls), red squares (ML) or green triangles (AK). Vertical dotted line and 
dashed/dotted indicate thresholds of 2 and 3 SDs above mean of values obtained with 
control plasma samples of US donors. Grey shading indicates samples with OD values 
exceeding mean + 3 SD threshold. Inserted tables show correlation (r-value) between OD 
and traversal inhibition for each group of samples and statistical significance (p-values), 
both calculated using GraphPad Prism correlation function. “Diamond” symbols in table 
and arrows on scatterplot indicate 2 outliers from ML group as defined by Grubb’s outlier 
test, which were removed from correlation calculations.  
4.3.3 Effect of plasma on in vitro infection of human hepatocytes 
Sporozoite traversal reflects the capacity of sporozoites to migrate through 
hepatocytes and can be used to assess sporozoite motility in vitro. Productive infection, 
however, requires both invasion and successful establishment of the parasitophorous 
vacuole (PV) followed by replication within. Therefore, we assessed the effect of human 
plasma on the development of P. falciparum 3D7HT-GFP EEFs, measured as the percent 
of GFP+ cells 48h pi. HC-04 hepatocytes were infected with P. falciparum sporozoites 
either simultaneously with or prior to addition of plasma. Overall, the presence of Malian 
plasma during sporozoite infection controlled EEF development versus normal human 
serum, this effect, however, was not statistically significant (95% CI 0.0127% - 0.0269%, 
NHS mean = 0.0234%, p = 0.158) (Figure 4.3A) and rather reflected the findings that 
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treatment with only some of AK plasma samples, such as AK48 and AK56, led to a 
decrease in the number of infected cells. 
To the contrary, when plasma was added 2 h pi, after removing uninvaded 
sporozoites, EEF development was significantly enhanced overall compared to normal 
human serum control, though to a small degree (95% CI 0.02789% – 0.03860%, NHS 
mean= 0.0244%, p = 0.0058). This demonstrates, that a large pool of Malian plasma 
samples facilitated development of EEFs when used under experimental conditions 
precluding direct effects on sporozoites prior to invasion. This time-dependent effect of 
plasma is illustrated in Figure 4.3B. Interestingly, AK48 and AK56 plasma exhibited the 
greatest difference in their opposing effect when added at 0 h (decrease in %GFP+ cells) 




Figure 4-3. Effect of plasma from Malian donors on P. falciparum EEF development in vitro. 
(A) HC-04 cells were infected with P. falciparum 3D7-HTGFP in the presence of plasma 
from indicated donor added either simultaneously with sporozoites (0-48) or 2 h pi (2-48) 
after cells were washed and uninvaded sporozoites were removed. The percentage of 
infected GFP+ HC-04 cells was determined by flow cytometry 48 h pi. Dotted line 
indicates level of infection observed in hepatocyte cultures infected in the presence of 
normal human serum (NHS). Values * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001 were calculated using one-way ANOVA, and Fisher’s LSD to compare effect of 
plasma from indicated Malian donor and commercial NHS. (B) Comparison of effect of 
each plasma sample on infection rate (%GFP) when added to HC-04 cells simultaneously 
with sporozoites (0-48) or beginning 2 h pi (2-48). ML, red squares; AK, green triangles. 














































































4.3.4 T cell composition 
The viability of cells recovered following thaw for each donor ranged from 0 to 
80% as measured by trypan blue exclusion. The number of recovered cells ranged from 0 
- 106 per donor. Thirty-eight out of 45 (84%) donors had sufficient viable PBMCs to 
perform ELISpot and flow cytometric analysis of T cell composition and HLA-A*02 
status. The size of CD4+ and CD8+ T cell compartments in PBMCs from Malian donors 
varied significantly from that of control US donors (Fig 4.4A). Within CD3+ 
lymphocytes, Malian samples had lower percentages of CD4+CD8- (Mali mean 38.1%, 
US mean 66.0%), higher percentages of CD8+CD4- (Mali mean 44.7%, US mean 20.3%), 
significantly higher percentages of CD4+CD8+ (Mali mean 11.5%, US mean 2.79%), 
and significantly lower percentages of CD4-CD8- (Mali mean 5.78%, US mean 10.9%) 
cells compared to US samples, though the high amount of double negative T cells in the 
US controls was skewed by two outliers. Skewed CD4+:CD8+ ratios were observed in 
PBMCs from Malian donors (Mali mean 0.997, US mean 3.30). While the mean ratio 
was strongly affected by outliers in the US donors, the median ratio the median also 
indicates that the CD4+:CD8+ ratio in PBMCs from Malian donors was lower than those 




Figure 4-4. Lymphocyte subsets in PBMCs from Malian donors. 
The following subsets of CD3+ lymphocytes were quantified by flow cytometry in 
PBMCs from US control donors or Malian donors from AK and ML cohorts: CD8-CD4+ 
(A), CD8+CD4- (B), CD8+CD4+ (C) and CD4-CD8- (D). CD4:CD8 ratio for each group 
of donors is shown in (D). Values * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p≤ 0.0001 




4.3.5 IFNγ production in PBMCs following stimulation with viral and CSP-
derived peptides 
PBMCs from Malian donors were stimulated ex vivo to determine the presence of 
CSP-specific memory T lymphocytes. Using a positivity threshold of 2 standard 
deviations above the mean number of spots for all control DMSO-stimulated samples, we 
found that PBMCs from 16/38 (42%) of Malian donors produced IFNγ following 
stimulation with a control pool of viral HLA class I-restricted peptides CEF (Figure 5A, 
B). This is far lower than the published 88% of expected responders (Currier et al. 2002). 
This could be due to a mismatch between the HLA haplotypes of donors’ PBMCs used in 
our study and the MHC restrictions of viral epitopes included in CEF, low amount of 
responding PBMCs used in our assay, as only 40,000 – 50,000 PBMCs were plated per 
well due to limited numbers available, or broad immune suppression in T cell 
compartment of Malian donors. 
Two methods were used to determine CSP-specific IFNγ responses: stimulation 
with Pfenex rCSP to induce cross presentation, and with selected HLA-A*02-restriced 9- 
and 10-mer peptides from CSP. Stimulation with Pfenex rCSP yielded IFNγ production 
in 6/38 (15.7%) of donors when 3 SD threshold positivity approach was applied for 
analysis, and in 8/38 (21%) of donors using 2 SD threshold (Figure 4.5 A, B). Four of the 
six “high responders” also responded to CEF, but two did not (ML24, AK58). This 
suggests that these two “CEF non-responders” were indeed capable of antigen-specific 
stimulation, but may not have recognized the CEF peptides.  
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Twelve of 38 (32%) donors were HLA-A*02-positive as determined by flow 
cytometry (Figure 4.5A). However, the anti-HLA-A*02 monoclonal antibody BB7.2 has 
been shown to bind HLA-A*69, -A*68, -A*23, and -A*24 as well (Hilton & Parham 
2013). Therefore, this may be an overestimate of the frequency of HLA-A*02 in our 
study, which was determined to be only 21% of the larger Malian population under study 
(Cao et al. 2004).  As an alternative determination of the HLA-A*02 haplotype and 
presence of functional HLA-A*02-restricted CD8+ responses, PBMCs were stimulated 
with only the HLA-A*02-restricted viral peptides contained within CEF (“Viral A2”).  
The number of responders was the same as to Pfenex rCSP (Figure 4.5B). Four of six 
samples that responded to the viral HLA-A*02-restricted peptides were also HLA-A*02+ 
by flow cytometry. The PBMCs that were defined as HLA-A*02 negative could bind the 
selected peptides on cross-reactive HLA alleles. Four of six responders to viral HLA-
A*02-restricted peptides also responded to CEF control peptides. The total amount of 
protein used for stimulation with CEF and the Viral A2 peptides was identical; therefore, 
a greater amount of each individual peptide was included in the Viral A2 pool, possibly 
explaining the absence of IFNγ production upon stimulation with CEF. 
CSP epitopes were chosen based on documented binding to HLA-A*02, IFNγ 
production or cytolytic activity following stimulation in naturally exposed or immunized 
volunteers, or predicted binding (Blum-Tirouvanziam et al. 1995; Doolan et al. 2000; 
González et al. 2000; Sedegah et al. 2013). Four of 38 PBMCs samples responded to the 
CSP-derived HLA-A*02-restricted peptide pool: ML11, ML22, AK47, and AK51 
(Figure 4.5A,B). PBMCs from donors ML11 and AK47 responded to all stimulation 
conditions and expressed surface HLA-A*02. Therefore, these donors may be of utility 
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for the generation and expansion of CSP-specific CD8+ T cell lines for in vitro studies of 
presentation and cytotoxicity in infected or traversed hepatocytes. 
 
 
Figure 4-5. Detection of CSP-specific T cell responses in PBMCs from Malian donors. 
(A) IFNγ responses were detected by ELISpot assays following stimulation of PBMCs 
with PHA, CEF control peptide pool, peptides spanning the full length of CSP (CSPfull), 
HLA-A*02-restricted viral peptides (Viral A2), or HLA-A*02-restricted peptides derived 
from CSP (CSP A2). Solid boxes indicate samples with number of spots exceeding 3 SD 
above the mean value derived from all unstimulated control samples propagated in 
DMSO (vehicle control). Dotted boxes indicate samples with number of spots exceeded 2 
standard deviations (as described above). Horizontal lines indicate PBMC sample that 
was not tested (NT) due to insufficient cell viability to perform assay. Values below 
tables indicate number of responders to each antigenic stimulus, using cutoff above 2 SD 
of DMSO control (top row) and percent of responders to each specific stimulus relative to 
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a number of PHA-responders (bottom row). HLA-A*02 status is indicated for each 
PBMC sample (black boxes). (B) Bar graph summarizes the percent of responders to 
each antigenic stimulus in ML and AK Malian cohorts combined relative to the number 
of all PHA-responders. 
4.3.6 Increased PD-1 expression in Malian PBMCs 
To possibly explain the infrequent overall responses to viral peptides in Malian 
samples, PBMCs were stained for inhibitory signaling receptors PD-1 (Figure 4.6) and 
Tim3 (data not shown). While surface expression of Tim3 was undetectable, PD-1 
expression was significantly increased in Mali versus US control PBMCs (Figure 4.6A). 
The most notable increase in PD-1+ cells was within the CD4+CD8- and CD4-CD8- 
populations (Figure 4.6A,B). The majority of double positive, CD4+CD8+ T cells in 
PBMCs from both populations were PD-1+. However, this population comprises a more 
substantial portion of Malian versus US PBMCs (Figure 4.4C). Overall, increased PD-1 
expression in the T cell compartment suggests a broad regulatory phenotype within 
Malian PBMCs not limited to malaria-specific T cells. 
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Figure 4-6. PD-1 expression on T lymphocytes from Malian and US donors 
(A) Percentage of PD-1 positive cells within each indicated T cell subset of US and 
Malian donors was determined by surface staining and flow cytometry.  Values * p ≤ 
0.05, *** p ≤ 0.001, **** p ≤ 0.0001 were obtained using student’s T-test. (B) 
Representative FACS plots illustrating PD-1 expression within each CD8+ and CD4+ 





4.3.7 Trans-effect of Malian plasma on malaria-naïve PBMCs 
PBMCs from US donors were propagated in the presence of plasma from 
allogeneic US or Malian donors to investigate if the altered T cell subsets and PD-1 
expression seen in Malian PBMCs could be induced in trans. Only one of three malaria-
naïve PBMC samples tested, (US 3) had a tendency toward altered CD4+:CD8+ ratio 
following treatment with Malian plasma (Figure 4.7). However, these differences, though 
statistically significant, were subtle and did not match those seen in PBMCs from Malian 
donors. Interestingly, incubation of US3 PBMCs in the presence of Malian plasma 
significantly increased the pool of CD4-CD8- cells (Figure 4.7). However, a functional 




Figure 4-7. Trans-effect of plasma from Malian donors on T cell composition in PBMCs from US 
donors 
PBMCs from three US control donors (US2, US3, US4) were propagated for five days in 
either serum-free AIM-V medium or AIM-V medium containing 10v/v% of plasma from 
US control or Malian donors. T cell subset composition was assessed by flow cytometry 
as described in Materials and Methods. Scatter plots indicate CD4+CD8-, CD8+CD4-, 
CD4+CD8+, and CD4-CD8- subsets as percentages of total CD3+ cell pool found in each 
indicated “normal” PBMC sample upon different treatment conditions. Value * p ≤ 0.05, 
** p ≤ 0.01 was obtained using student’s T-test. 
Next, we assessed the ability of plasma from Malian donors to regulate PD-1 
expression on PBMCs. Again, each PBMC donor exhibited different responses to US and 
Malian plasma (Figure 4.8). CD4+ and CD8+ T cells from Donor 3 slightly increased 
PD-1 expression when exposed to Mali serum, and US 4 had a reduction in PD-1+ cells, 
but these differences did not exceed one percent. These studies suggest that circulating 
plasma factors in healthy adults from Mali likely do not exhibit biologically meaningful 



















































































































































Figure 4-8. Trans-effect of plasma from Malian donors on PD-1 expression by PBMCs from US 
donors 
PBMCs from three US control donors (US2, US3 and US4) were propagated for five 
days in either serum-free AIM-V medium or AIM-V medium containing 10v/v% of 
plasma from randomly selected US control or Malian donors. PD-1 expression within 
each indicated T cell subset was determined by flow cytometry. Scatter plots indicate 
percentage of PD-1 positive cells of CD3+ lymphocyte subsets (left, CD4+; right, CD8+) 
found in each indicated US PBMC sample upon different treatment conditions. Value 
*** p ≤ 0.001 was obtained using student’s T-test. 
4.3.8 PD-1 blockade increases response of Malian PBMCs to T cell 
receptor triggering 
To assess a function associated with the observed increased PD-1 expression by 






























































































































were subject to antibody-based PD-1 blockade prior to TCR triggering with anti-CD3 and 
anti-CD28 stimulation. In donor AK48, PD-1 blockade increased the percent of CD4+ 
cells secreting IFNγ from 4.67% to 7.68%, and from 57.5% to 64.8% of CD8+ cells. This 
pilot test of PD-1 blockade shows promise for enhancing cytokine secretion from T cells, 




Figure 4-9. Effect of PD-1 blockade on response to TCR triggering of PBMCs from Malian donor. 
PBMCs from Malian donor AK48 incubated overnight with PD-1 blocking antibody or 
IgG1 isotype control antibody were stimulated with anti-CD3 and anti-CD28 beads 
followed by detection of secreted IFNγ by flow cytometry. Bar graphs indicate 
percentages of CD4+ and CD8+ cells secreting IFNγ.  
4.3.9 PD-1 blockade increases response of Malian PBMCs to CSP-derived, 
MHC-I-restricted peptides 
Next, we sought to determine if interfering with PD-1-based interactions of T 
cells with APCs could modulate malaria-specific CD8+ T cell responses. We selected 
HLA-A*02-positive donors with previously undetectable IFNγ production following 

































































presence of PD-1-specific (or isotype control) antibodies. PD-1 blockade in two of three 
Malian donors tended to increase the number of cells secreting IFNγ following 
stimulation with CSP-specific HLA-A*02-restricted peptide pools, though not 
statistically significantly (Figure 4.10). These data will be extended to additional PBMC 
donors in the future to assess the functional effects of increased PD-1 expression by T 
cells. 
 
Figure 4-10 Effect of PD-1 blockade on response to CSP-specific, MHC-restricted stimulation of 
PBMCs from Malian donors. 
PBMCs from US control and Malian donors were stimulated with viral control or CSP-
specific peptides for 20 h in the presence of PD-1 blocking antibody or IgG1 isotype 
control antibody, followed by detection of IFNγ-producing cells by ELISpot. Bar graphs 





To understand the nature of CSP-specific memory T cell responses induced 
during natural infection with malaria, we analyzed plasma and PBMC recall responses in 
healthy adults from Mali. We first assessed evidence of exposure to P. falciparum, as IgG 
against blood stage antigens MSP-1 and MSP-2. It is documented that ninety percent of 
populations living in malaria-endemic regions of Mali are exposed to multiple infectious 
mosquito bites each season (World Health Organization 2014). In line with this 
observation, we found evidence of humoral responses to MSP-1 and MSP-2 in 78% of 
the 45 subjects in our study (Figure 4.1B). While it was expected that the entire 
population samples would have experienced malaria illness during childhood and been 
exposed each season, antibody titers are associated with current or recent blood stage 
infection (Proietti et al. 2013). Accordingly, 90% of the post-transmission season AK 
cohort, and 68% of the pre-transmission season ML cohort had detectable titers to MSP-1 
and MSP-2 (Figure 4.1B).  
With evidence of previous malaria infection, we investigated the presence CSP-
specific IgG. Most studies screening for CSP IgG by ELISA solely rely on peptides of the 
repeat region (Clement et al. 2012). Because we were primarily interested in assessing 
CTL responses to previously identified peptide epitopes derived from the N- and C-
termini, we expanded these methods to assess humoral responses against the termini by 
including a nearly full length recombinant protein, and peptides spanning the N-terminal 
signal peptide and C-terminus that were not included in the commercially available full-
length recombinant CSP (Figure 4.1A). As the central repeat region is recognized to 
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contain an immunodominant epitope of CSP (Zavala et al. 1983; Dame et al. 1984), it 
was not surprising that the number of subjects recognizing the more inclusive Pfenex 
rCSP and (NANP)x7 peptides were nearly identical. Nearly all donors with IgG 
specifically recognizing the (NANP)x7 peptide indeed were also positive for IgG against 
Pfenex rCSP (Figure 4.1B). Fewer plasma samples had IgG specific to the abbreviated N- 
and C-termini tested, and the number of positive samples tended to be higher in the post-
season AK group (Figure 4.1C). This finding is in agreement with other studies showing 
that anti-malaria antibodies are short-lived and increase after each transmission season, 
though these documented differences are greater in children than in adults (Crompton et 
al. 2010).   
Since we detected antibody responses to CSP, which is abundantly expressed on 
the sporozoite surface, we next assessed the functional effect of Mali plasma samples on 
in vitro infection of hepatocytes. As compared to infection in the presence of FCS, the 
addition of human plasma during invasion, whether from exposed or non-exposed 
individuals, inhibited sporozoite motility (Figure 4.2A). This inhibition, as measured by 
traversal, was specific to P. falciparum and not the rodent parasite, P. berghei. However, 
this inhibition did not correlate with the presence or magnitude of anti-CSP antibodies 
measured by ELISA (Figure 4.2C, D). Interestingly, this finding differed from other 
reports indicating that inhibition of motility correlated with the concentration of 
monoclonal anti-CSP antibodies or IgG purified from vaccinated human subjects (Foquet 
et al. 2013; Behet et al. 2014; Finney et al. 2014). However, since vaccines are designed 
to deliver antigen in an optimally immunogenic manner, inducing sufficiently high 
amounts of memory B cells, the function of vaccine-induced antibodies may have greater 
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neutralizing capacity than those induced in natural exposure. Thus, the possible 
component(s) of plasma beyond CSP-specific antibodies from Malian donors that impair 
motility of sporozoites in vitro have yet to be identified. In the future, we intend to 
deplete IgG from these plasma samples to see if this effect is antibody-mediated. The 
specificity for impairment of P. falciparum versus P. berghei sporozoite motility suggests 
an antigen-specific plasma factor.  
We also assessed the effects of human plasma on EEF development, using a 
smaller panel of randomly selected samples. We observed an overall decrease in 
percentage of GFP-positive cells when adding plasma during sporozoite invasion, and an 
increase when adding plasma post-invasion (Figure 4.3A,B). However, these findings 
should be repeated using a greater number of samples to understand this phenomenon.  
With experimental evidence that the PBMCs from Malian donors had been 
exposed to and developed humoral responses against CSP, we next assessed T cell 
responsiveness. We characterized the composition of CD4+ and CD8+ subsets of the 
CD3+ compartment in peripheral blood, and observed lower CD4+:CD8+ ratios and a 
higher percent of CD4+CD8+ cells, as compared to US control donors (Figure 4.4). We 
then screened for responses to control viral peptides, full-length CSP, or selected HLA-
A*02-restricted peptide epitopes derived from CSP by IFNγ ELISpot.  
We observed lower than the expected population-wide 89% of responses to viral 
peptide pool CEF (Currier et al. 2002) (Figure 4.5). This could be due to many reasons, 
primarily 1) 50,000 PBMCs were used per stimulation due to poor viability and 
availability of the specimens, less than ideal for detection of rare antigen-specific cells or 
2) immune dysregulation affecting T cell responsiveness. Mali is one of the poorest 
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countries in the world, burdened by malnutrition and many other infections besides 
malaria, which can alter adaptive immunity. Chronic exposure to malaria is associated 
with both B- and T-cell exhaustion, with strong implications for inhibitory T cell 
signaling receptor, PD-1 (Weiss et al. 2009; Illingworth et al. 2013; Butler et al. 2011).  
Therefore, we investigated the expression of PD-1 on PBMCs, and if exposure of PBMCs 
from malaria-naïve control US donors to Malian plasma could alter expression of CD4, 
CD8, and PD-1. We found increased expression of PD-1 on PBMCs from Malian donors, 
mostly observed in the population of double positive, CD4+CD8+ cells that was more 
prominent in Malian donors (Figure 4.6).  This population of peripheral double positive 
cells is rarely seen in healthy individuals, but is detected in several conditions associated 
with immune deficiency, such as HIV, aging, and chronic viral infection or parasitic 
infection, and are often dysfunctional (Giraldo et al. 2011; Zuckermann 1999; Parel & 
Chizzolini 2004). The propagation of US control PBMCs in the presence of plasma from 
Mali on occasion, did lead to slight, but likely functionally irrelevant, changes in the 
CD4+ and CD8+ frequencies, and PD-1 expression warranting further examination of 
plasma factors that may affect T cell homeostasis (Figure 4.7, 8).  
To explore a potential therapeutic solution to the speculated immune dysfunction, 
we stimulated the PBMCs of one Mali donor following antibody-based blockade of PD-1 
(Figure 4.9). Following anti-CD3 and anti-CD28 TCR triggering, we observed increases 
in the percentage of IFNγ-secreting CD4+ and CD8+ single-positive populations. We 
applied these preliminary findings to the assessment of PD-1 blockade during CSP-
specific stimulation (Figure 4.10), and observed potential increased cytokine secretion. 
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These studies will be expanded by including additional donors, utilizing CSP-specific, 
MHC-I-restricted stimulation in HLA-A*02-positive donors. 
We detected CSP-specific IFNγ responses from either stimulation with full-length 
CSP or HLA-A*02-restricted peptides, in four of 38 donors. This low frequency is 
comparable to other studies, and could be a result of both low frequency of specific cells, 
and the dysregulation of the T cell compartment we observed and speculated to be 
generally immune suppressive. PBMCs from two donors were HLA-A*02+ by surface 
staining and flow cytometry, and responded specifically to control and CSP-derived 
peptides. Therefore, the PBMCs from this donor could serve a useful tool for the studying 
of CSP-specific presentation to CTLs. They should be carefully examined for fine 
peptide-epitope specificities, and expanded if possible, for the generation of CSP-specific 
CTL lines. 
 Altogether, our findings on the frequencies of naturally induced antibody and T 
cell responses to CSP are in line with similar studies in other populations. It is important 
to conduct these immune-epidemiological studies in different populations from endemic 
areas, because each cohort is exposed to a different set of transmission dynamics, co-
morbidities, and genetic diversity in parasites, and expresses varying HLA haplotypes. 
All these environmental and genetic factors are important in defining overall immune 
responses, as well as anti-malarial immunity. Understanding the development of effective 
anti-malarial immunity in endemic populations is crucial for designing a successful 
vaccine for this target population. 
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Chapter 5. CONCLUSIONS 
5.1 Novel roles for traversed hepatocytes 
5.1.1 Traversed hepatocytes as antigen depots 
We have described novel findings relevant to CSP-specific T cell responses, 
which we propose to be meaningful for malaria vaccine development. In Chapter 2, we 
presented in-depth studies of sporozoite traversal-mediated deposition of leading vaccine 
candidate, CSP, into hepatocytes. Notably, these analyses were performed in an in vitro 
model using human hepatocytes and the most lethal parasite afflicting humans, P. 
falciparum. While this model is infrequently utilized in the laboratory due to its technical 
and biosafety-related challenges, we believe it is appropriate to studying both cell biology 
and immunology of human malaria infection.  
We showed that hepatocytes traversed by sporozoites in vitro are viable, retain 
CSP for an extended duration with dynamic subcellular localization, and degrade CSP 
using multiple proteolytic machineries. We suggest that searches for other antigens 
potentially deposited into traversed hepatocytes should be conducted as well. The 
retention of sporozoite- and liver-stage antigen in traversed, but non-invaded cells offer 
the intriguing possibility of presentation to CTLs in the environment of the liver located 
close to invaded cells with developing parasites, the desirable target of cytotoxicity or 
parasite control. 
5.1.2 Traversed hepatocytes as non-professional antigen presenting cells 
The liver is characterized overall as immune tolerant. Perhaps, this is one of the 
reasons why Plasmodium sporozoites evolved to develop in the mammalian liver. 
 138 
However, data do remain controversial on T cell activation and effector functions within 
this organ (reviewed in (Crispe 2009)). Having shown that traversed cells contain at least 
one malarial antigen, we evaluated the antigen presenting capacity of traversed 
hepatocytes as well as their potential to alter effector function of nearby CTLs, discussed 
in Chapter 3. We found that traversed HC-04 hepatocytes maintained unaltered levels of 
MHC class I and co-stimulatory ICAM and stimulated a full array of T cell activation 
programs upon antigen-specific, MHC class I-restricted stimulation.  At least in this in 
vitro system, traversed cells exhibited no apparent defect or enhancement in the ability to 
stimulate CTL effector functions. Furthermore, utilizing a human CTL line specific for a 
C-terminal peptide of CSP, we showed that traversed cells could present this peptide 
epitope to induce IFNγ secretion. While this in vitro system of identification of traversed 
cells is technically unable to distinguish traversed cells that may contain parasites, 
possibly aborted or developing, we believe that this is the first demonstration of CSP 
presentation from traversed cells. The future use of rodent parasite models and parasites 
that are only able to invade but not traverse (Ishino et al. 2005) will allow further 
identification of the source of liver stage antigen to CTLs. The generation of additional 
CSP-specific CD8+ T cells would permit the determination of which other peptide 
epitopes may be presented from traversed, as well as infected hepatocytes. 
We speculate on possible implications of the presentation of malarial antigens 
from traversed hepatocytes in the liver. In vitro, we observe far greater numbers of 
traversed than invaded hepatocytes. If this finding is recapitulated in vivo situation at 
least partially, then the presence of traversed cells presenting malarial antigens may 
increase overall activation of T cells specific for shared antigens present in both traversed 
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and invaded hepatocytes. This could, consequently, lead to greater secretion of cytokines 
IFNγ and TNFα, which are known to be important in limiting infection. Alternatively, 
traversed cells could divert and engage malaria-specific CTLs as decoys, limiting direct 
killing of infected hepatocytes. We expect that exciting developments in intravital 
imaging studies in the near future may help elucidate the architecture of traversed and 
invaded cells in the liver, and in turn, the dynamics of CTL recruitment and engagement 
with both populations of hepatocytes. If traversal serves an overall benefit to the host in 
controlling EEF development, such findings would support the further investment in 
generation of attenuated sporozoite vaccines that could traverse hepatocytes. 
Importantly, our speculation on traversed hepatocytes as antigen presenting cells 
relates purely to the activation of memory T cells; we do not posit a role for traversed 
hepatocytes in priming of CD8+ T cells.  
5.2 Consideration of existing immunity in vaccine development 
We focused our studies on CTL responses against CSP because there is a 
tremendous amount of data from experimental models of malaria vaccination that 
demonstrate crucial roles for CD8+ immunity to liver stage, and CSP in particular. 
However, in developing a vaccine, it is essential to consider the immune status of the 
target population receiving the vaccine. The acquisition of partial but incomplete 
immunity to malaria in endemic regions has been noted throughout history. Children 
under the age of five are generally the victims of most severe disease and fatality. With 
continued exposure, however, the gradual development of partial immunity protects 
against severe disease. Considering the most clinically advanced vaccine, RTS,S, is only 
somewhat efficacious, interesting and concerning questions remain as to the 
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consequences of administering a partially protective vaccine in an endemic region: would 
it follow that it would partially reduce malaria burden, or have the opposite, potentially 
dangerous effect, of interfering with the development of naturally acquired immunity that 
is known to be protective, increasing the disease burden, doing more harm than good?  
It is clear that immune responses to natural exposure and vaccination vary, in the 
degree of protection, as well as in the underlying immune mechanisms induced. Part of 
our study (Chapter 4), revealing a lack of correlation between anti-CSP IgG titers in 
naturally exposed donor plasma, and inhibition of sporozoite motility, illustrate this point. 
In vaccination studies, there is a dose-dependent relationship between inhibition of 
sporozoite motility by both monoclonal antibodies against CSP as well as the 
concentration of total IgG from vaccinated, protected individuals. This suggests that the 
neutralizing capacity of anti-sporozoite antibodies differ in natural exposure and in 
vaccination, in agreement with findings by Hoffman and colleagues (Hoffman et al. 
1987). As we found evidence of dysregulated T cell responses in healthy adults residing 
in malaria endemic area, manifested as increased CD4+CD8+ populations in peripheral 
blood and PD-1 expression, as well as lower than expected responses to stimulation with 
viral peptides, we speculate that a vaccine should incorporate components to overcome 
the naturally regulatory responses to try to create a more protective, unnatural immune 
response.  
Altogether, our studies advance the relatively recent understanding of sporozoite 
traversal through hepatocytes, suggesting potential roles for traversed hepatocytes in 
CD8+ T cell immunity. We also comprehensively investigated humoral responses and 
their functions in sporozoite infection, detected cellular responses specific to CSP, and 
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characterized phenotype and responsiveness of T cells circulating in peripheral blood of 
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